{ "instance": { "srne-20211231.htm": { "axisCustom": 0, "axisStandard": 49, "contextCount": 491, "dts": { "calculationLink": { "local": [ "srne-20211231_cal.xml" ] }, "definitionLink": { "local": [ "srne-20211231_def.xml" ] }, "inline": { "local": [ "srne-20211231.htm" ] }, "labelLink": { "local": [ "srne-20211231_lab.xml" ] }, "presentationLink": { "local": [ "srne-20211231_pre.xml" ] }, "schema": { "local": [ "srne-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 951, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 4, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 8 }, "keyCustom": 131, "keyStandard": 500, "memberCustom": 109, "memberStandard": 58, "nsprefix": "srne", "nsuri": "http://sorrentotherapeutics.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Cover", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Fair Value Measurements", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_52b93e67-04f9-4e29-a750-1edc5e64b4cd", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101020 - Disclosure - Loss Per Share - Reconciliation of Basic and Diluted Earnings Per Share (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareReconciliationOfBasicAndDilutedEarningsPerShareDetails", "shortName": "Loss Per Share - Reconciliation of Basic and Diluted Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_a003a66a-1384-4334-bc72-9237aae8a254", "decimals": "-3", "lang": null, "name": "us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersDiluted", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_5ba2f26d-875a-4782-aae2-7258be2c563f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101030 - Disclosure - Loss Per Share - Outstanding Securities (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareOutstandingSecuritiesDetails", "shortName": "Loss Per Share - Outstanding Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_5ba2f26d-875a-4782-aae2-7258be2c563f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_d7c93619-7e7e-4571-8da1-4bc6715efe82", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101040 - Disclosure - Subsequent Events - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "shortName": "Subsequent Events - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_d7c93619-7e7e-4571-8da1-4bc6715efe82", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Property and Equipment", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Investments", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Goodwill and Intangible Assets", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "srne:SignificantAgreementsAndContractsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Significant Agreements and Contracts", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContracts", "shortName": "Significant Agreements and Contracts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "srne:SignificantAgreementsAndContractsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Debt", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Stockholders' Equity", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity1", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Stock Incentive and Employee Benefit Plans", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans", "shortName": "Stock Incentive and Employee Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Commitments and Contingencies", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Income Taxes", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Consolidated Balance Sheets", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Related Party Agreements and Other", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOther", "shortName": "Related Party Agreements and Other", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Segment Information", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Quarterly Financial Data (Unaudited)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureQuarterlyFinancialDataUnaudited", "shortName": "Quarterly Financial Data (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Loss Per Share", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShare", "shortName": "Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Subsequent Events", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEvents1", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "srne:DescriptionOfBusinessPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Organization and Significant Accounting Policies (Policies)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies", "shortName": "Organization and Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "srne:DescriptionOfBusinessPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Organization and Significant Accounting Policies (Tables)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesTables", "shortName": "Organization and Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Fair Value Measurements (Tables)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Property and Equipment (Tables)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Debt (Tables)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Stock Incentive and Employee Benefit Plans (Tables)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansTables", "shortName": "Stock Incentive and Employee Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Income Taxes (Tables)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Segment Information (Tables)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureQuarterlyFinancialDataUnauditedTables", "shortName": "Quarterly Financial Data (Unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Loss Per Share (Tables)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables", "shortName": "Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Organization and Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_d02bcfd7-a55f-400e-804b-0c7ab4f6352e", "decimals": null, "lang": "en-US", "name": "srne:RevenuePerformanceObligationSatisfiedOverTimePeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_52b93e67-04f9-4e29-a750-1edc5e64b4cd", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Organization and Significant Accounting Policies - Schedule of Revenues by Category (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesScheduleOfRevenuesByCategoryDetails", "shortName": "Organization and Significant Accounting Policies - Schedule of Revenues by Category (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_49ba254f-279f-4d56-a920-4eeac3caa187", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_2699bb9c-406a-49a0-9cf3-b6a7fa3521f0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_2699bb9c-406a-49a0-9cf3-b6a7fa3521f0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Consolidated Statements of Operations", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesIssued", "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_a51a89ab-417b-40ea-91bd-a02c2b2ba828", "decimals": "-5", "lang": null, "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_3c7fc13a-59d0-4240-a412-aca7ac29b1fc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Fair Value Measurements - Summary of Contingent Consideration Liabilities are Measured at Fair Value Using Significant Unobservable Inputs (Level 3) (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentConsiderationLiabilitiesAreMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3De", "shortName": "Fair Value Measurements - Summary of Contingent Consideration Liabilities are Measured at Fair Value Using Significant Unobservable Inputs (Level 3) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_35d6743e-780d-4489-b608-fe95bd7ec943", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_3c7fc13a-59d0-4240-a412-aca7ac29b1fc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Fair Value Measurements - Summary of Derivative Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3Details", "shortName": "Fair Value Measurements - Summary of Derivative Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_6cc0a443-7fb0-4201-8b03-776673a6723e", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails", "shortName": "Property and Equipment - Summary of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Property and Equipment - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails", "shortName": "Property and Equipment - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Investments - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "shortName": "Investments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Investments - Celularity - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "shortName": "Investments - Celularity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_7b664a63-3478-4431-8005-e7263b745f8c", "decimals": "-5", "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Investments - NANTibody - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails", "shortName": "Investments - NANTibody - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_6d06fe23-c73c-4319-b66f-64478683d2df", "decimals": "2", "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Investments - NantStem - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantstemAdditionalInformationDetails", "shortName": "Investments - NantStem - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_01702336-356e-4642-9563-9f1b55462c3b", "decimals": "2", "lang": null, "name": "srne:EquityMethodInvestmentVotingInterest", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "shortName": "Goodwill and Intangible Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-5", "lang": null, "name": "us-gaap:GoodwillPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Consolidated Statements of Comprehensive Loss", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Goodwill and Intangible Assets - Summary of Company's Identifiable Intangible Assets (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets - Summary of Company's Identifiable Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense Related to Intangible Assets (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense Related to Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Significant Agreements and Contracts - Acquisition of ACEA Therapeutics, Inc. - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "shortName": "Significant Agreements and Contracts - Acquisition of ACEA Therapeutics, Inc. - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_35d6743e-780d-4489-b608-fe95bd7ec943", "decimals": null, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_7a512dfd-0cda-4cf4-9739-e389c2000677", "decimals": "-5", "first": true, "lang": null, "name": "srne:UpFrontLicenseFee", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Significant Agreements and Contracts - Asset Purchase Agreement with Aardvark Therapeutics, Inc. - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAssetPurchaseAgreementWithAardvarkTherapeuticsIncAdditionalInformationDetails", "shortName": "Significant Agreements and Contracts - Asset Purchase Agreement with Aardvark Therapeutics, Inc. - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_7a512dfd-0cda-4cf4-9739-e389c2000677", "decimals": "-5", "first": true, "lang": null, "name": "srne:UpFrontLicenseFee", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Significant Agreements and Contracts - Acquisition of SmartPharm Therapeutics, Inc. - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSmartpharmTherapeuticsIncAdditionalInformationDetails", "shortName": "Significant Agreements and Contracts - Acquisition of SmartPharm Therapeutics, Inc. - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_3d3076c3-e572-4b2f-b898-aba353d33a51", "decimals": "-5", "lang": null, "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_df9d9a35-da0a-4782-8bf0-0db0c9e60377", "decimals": "-5", "first": true, "lang": null, "name": "srne:AssetAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Significant Agreements and Contracts - Acquisition of Semnur Pharmaceuticals - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails", "shortName": "Significant Agreements and Contracts - Acquisition of Semnur Pharmaceuticals - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_df9d9a35-da0a-4782-8bf0-0db0c9e60377", "decimals": "-5", "first": true, "lang": null, "name": "srne:AssetAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentInProcess", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Significant Agreements and Contracts - Acquisition of Sofusa - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails", "shortName": "Significant Agreements and Contracts - Acquisition of Sofusa - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_13e0a404-9822-4fa5-843a-08cc818aa41d", "decimals": "-5", "first": true, "lang": null, "name": "srne:UpFrontLicenseFee", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Significant Agreements and Contracts - License Agreement with Icahn School of Medicine at Mount Sinai - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsLicenseAgreementWithIcahnSchoolOfMedicineAtMountSinaiAdditionalInformationDetails", "shortName": "Significant Agreements and Contracts - License Agreement with Icahn School of Medicine at Mount Sinai - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_13e0a404-9822-4fa5-843a-08cc818aa41d", "decimals": "-5", "first": true, "lang": null, "name": "srne:UpFrontLicenseFee", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_139cde28-d42f-41ff-b42b-e8b185a56fef", "decimals": "-5", "first": true, "lang": null, "name": "srne:UpFrontLicenseFee", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Significant Agreements and Contracts - License Agreement with ACEA Therapeutics, Inc - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithACEATherapeuticsIncAdditionalInformationDetails", "shortName": "Significant Agreements and Contracts - License Agreement with ACEA Therapeutics, Inc - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_139cde28-d42f-41ff-b42b-e8b185a56fef", "decimals": "-5", "first": true, "lang": null, "name": "srne:UpFrontLicenseFee", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_16de8706-fbb6-4041-8351-15ffd52ff8bb", "decimals": "-5", "first": true, "lang": null, "name": "srne:UpFrontLicenseFeePayableWithinTenBusinessDays", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Significant Agreements and Contracts - License Agreement with The Trustees of Columbia University in the City of New York - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithTheTrusteesOfColumbiaUniversityInCityOfNewYorkAdditionalInformationDetails", "shortName": "Significant Agreements and Contracts - License Agreement with The Trustees of Columbia University in the City of New York - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_16de8706-fbb6-4041-8351-15ffd52ff8bb", "decimals": "-5", "first": true, "lang": null, "name": "srne:UpFrontLicenseFeePayableWithinTenBusinessDays", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_59e2e797-f6a7-4f89-8733-5d73dc2a4883", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080 - Statement - Consolidated Statements of Stockholders' Equity", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_59e2e797-f6a7-4f89-8733-5d73dc2a4883", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_5762013e-8c6b-4207-944f-084a45a98db3", "decimals": "-5", "first": true, "lang": null, "name": "srne:UpFrontLicenseFee", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Significant Agreements and Contracts - License Agreement with Mayo Foundation - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails", "shortName": "Significant Agreements and Contracts - License Agreement with Mayo Foundation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_5762013e-8c6b-4207-944f-084a45a98db3", "decimals": "-5", "first": true, "lang": null, "name": "srne:UpFrontLicenseFee", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c0ea9af8-04a0-4710-bfa0-63388040c80b", "decimals": "-5", "first": true, "lang": null, "name": "srne:UpFrontLicenseFee", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Significant Agreements and Contracts - License Agreement with Personalized Stem Cells, Inc - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithPersonalizedStemCellsIncAdditionalInformationDetails", "shortName": "Significant Agreements and Contracts - License Agreement with Personalized Stem Cells, Inc - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c0ea9af8-04a0-4710-bfa0-63388040c80b", "decimals": "-5", "first": true, "lang": null, "name": "srne:UpFrontLicenseFee", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_d99c3b63-fb88-4de0-b1ce-9dc1b305dec0", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Significant Agreements and Contracts - License Agreement with NantCell - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails", "shortName": "Significant Agreements and Contracts - License Agreement with NantCell - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "srne:SignificantAgreementsAndContractsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_d99c3b63-fb88-4de0-b1ce-9dc1b305dec0", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromShortTermDebt", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Significant Agreements and Contracts - Short-Term Loans - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsShortTermLoansAdditionalInformationDetails", "shortName": "Significant Agreements and Contracts - Short-Term Loans - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_06d06500-9c47-4489-9834-60af8cb193b6", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Debt - 2018 Purchase Agreement and Indenture for Scilex - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "shortName": "Debt - 2018 Purchase Agreement and Indenture for Scilex - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4f7faf5e-5e34-4faa-8dac-25b69f68d443", "decimals": "INF", "lang": null, "name": "us-gaap:GuaranteeObligationsMaximumExposure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_3166bf84-527a-4d79-9004-cfd86217ee9b", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Debt - 2018 Purchase Agreement and Indenture for Scilex - Schedule of Long-Term Debt and Unamortized Discount Balances (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails", "shortName": "Debt - 2018 Purchase Agreement and Indenture for Scilex - Schedule of Long-Term Debt and Unamortized Discount Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_404f35eb-6107-4df5-aad3-b0669bc07d2a", "decimals": "-3", "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_3166bf84-527a-4d79-9004-cfd86217ee9b", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Debt - Future Minimum Payments (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails", "shortName": "Debt - Future Minimum Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_404f35eb-6107-4df5-aad3-b0669bc07d2a", "decimals": "-3", "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_06d06500-9c47-4489-9834-60af8cb193b6", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Debt - 2018 Oaktree Term Loan Agreement (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails", "shortName": "Debt - 2018 Oaktree Term Loan Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_f9f0aaac-983d-4f93-a87f-dca578cf6598", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_06d06500-9c47-4489-9834-60af8cb193b6", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Debt - 2018 Securities Purchase Agreement for Private Placement - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails", "shortName": "Debt - 2018 Securities Purchase Agreement for Private Placement - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_f46820d9-9aca-4c56-a02b-7f8fbc5eba46", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_83cc7601-caad-4aa0-8755-64654fc81bb4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Debt - 2020 Revolving Credit Facility - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails", "shortName": "Debt - 2020 Revolving Credit Facility - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_83cc7601-caad-4aa0-8755-64654fc81bb4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100090 - Statement - Consolidated Statements of Cash Flows", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_f6934efb-b043-4b5f-91b9-a31685fa9435", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Debt - ACEA Significant Debt Arrangements - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails", "shortName": "Debt - ACEA Significant Debt Arrangements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_f6934efb-b043-4b5f-91b9-a31685fa9435", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_404f35eb-6107-4df5-aad3-b0669bc07d2a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100730 - Disclosure - Stockholders' Equity - At-the-Market Sales Agreement - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "shortName": "Stockholders' Equity - At-the-Market Sales Agreement - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_1b69041a-5257-490f-b27c-f3b3eef0c3bd", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_0f3ee226-d98f-4552-b6af-83915e7a2283", "decimals": "INF", "first": true, "lang": null, "name": "srne:SaleOfStockMaximumAmountOfSharesAuthorizedToBeSold", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100740 - Disclosure - Stockholders' Equity - Common Stock Purchase Agreement - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockPurchaseAgreementAdditionalInformationDetails", "shortName": "Stockholders' Equity - Common Stock Purchase Agreement - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_0f3ee226-d98f-4552-b6af-83915e7a2283", "decimals": "INF", "first": true, "lang": null, "name": "srne:SaleOfStockMaximumAmountOfSharesAuthorizedToBeSold", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_228c60f3-437d-4b39-a0cb-7b7227142f08", "decimals": "-5", "first": true, "lang": null, "name": "srne:SaleOfStockMaximumAmountOfSharesAuthorizedToBeSold", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100750 - Disclosure - Stockholders' Equity - Aspire Transaction - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAspireTransactionAdditionalInformationDetails", "shortName": "Stockholders' Equity - Aspire Transaction - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_228c60f3-437d-4b39-a0cb-7b7227142f08", "decimals": "-5", "first": true, "lang": null, "name": "srne:SaleOfStockMaximumAmountOfSharesAuthorizedToBeSold", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_6e2e774e-c5b6-4bad-98b9-acbdff5ce209", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100760 - Disclosure - Stockholders' Equity - Equity Distribution Agreement - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityEquityDistributionAgreementAdditionalInformationDetails", "shortName": "Stockholders' Equity - Equity Distribution Agreement - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_6e2e774e-c5b6-4bad-98b9-acbdff5ce209", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_6cb5881a-ca83-4910-9aef-73081c7075a6", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100770 - Disclosure - Stockholders' Equity - 2019 Public Offering of Common Stock and Warrants - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity2019PublicOfferingOfCommonStockAndWarrantsAdditionalInformationDetails", "shortName": "Stockholders' Equity - 2019 Public Offering of Common Stock and Warrants - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_6cb5881a-ca83-4910-9aef-73081c7075a6", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_aa327372-e7ce-49cf-8a88-6a61489001ef", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100780 - Disclosure - Stockholders' Equity - 2019 Registered Direct Offering - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity2019RegisteredDirectOfferingAdditionalInformationDetails", "shortName": "Stockholders' Equity - 2019 Registered Direct Offering - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_aa327372-e7ce-49cf-8a88-6a61489001ef", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100790 - Disclosure - Stock Incentive and Employee Benefit Plans - 2019 Stock Incentive Plan - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails", "shortName": "Stock Incentive and Employee Benefit Plans - 2019 Stock Incentive Plan - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-5", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_3c7fc13a-59d0-4240-a412-aca7ac29b1fc", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100800 - Disclosure - Stock Incentive and Employee Benefit Plans - Summary of Stock Option Activity (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfStockOptionActivityDetails", "shortName": "Stock Incentive and Employee Benefit Plans - Summary of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_bc65acc1-3a5f-417e-8c43-d5e6ecc95761", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100810 - Disclosure - Stock Incentive and Employee Benefit Plans - Fair Value of Employee and Director Stock Options (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansFairValueOfEmployeeAndDirectorStockOptionsDetails", "shortName": "Stock Incentive and Employee Benefit Plans - Fair Value of Employee and Director Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_bc65acc1-3a5f-417e-8c43-d5e6ecc95761", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Organization and Significant Accounting Policies", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPolicies", "shortName": "Organization and Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100820 - Disclosure - Stock Incentive and Employee Benefit Plans - Summary of Restricted Stock Unit (\"RSU\") Activity (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfRestrictedStockUnitRsuActivityDetails", "shortName": "Stock Incentive and Employee Benefit Plans - Summary of Restricted Stock Unit (\"RSU\") Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "INF", "lang": null, "name": "srne:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100830 - Disclosure - Stock Incentive and Employee Benefit Plans - Scilex Holding Company - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansScilexHoldingCompanyAdditionalInformationDetails", "shortName": "Stock Incentive and Employee Benefit Plans - Scilex Holding Company - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_915c267e-1fa6-48b5-b3c4-c0fcd230b075", "decimals": "-5", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100840 - Disclosure - Stock Incentive and Employee Benefit Plans - Employee Stock Purchase Plan - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansEmployeeStockPurchasePlanAdditionalInformationDetails", "shortName": "Stock Incentive and Employee Benefit Plans - Employee Stock Purchase Plan - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_7fec99a4-36a6-424f-910f-870310e7aeac", "decimals": "2", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4f87a872-34ca-4bca-9449-4684fb91e580", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100850 - Disclosure - Stock Incentive and Employee Benefit Plans - CEO Performance Award - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails", "shortName": "Stock Incentive and Employee Benefit Plans - CEO Performance Award - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4f87a872-34ca-4bca-9449-4684fb91e580", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100860 - Disclosure - Stock Incentive and Employee Benefit Plans - Common Stock Reserved for Future Issuance - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCommonStockReservedForFutureIssuanceAdditionalInformationDetails", "shortName": "Stock Incentive and Employee Benefit Plans - Common Stock Reserved for Future Issuance - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_0d59846e-fd0f-4201-9177-9df66d319eb5", "decimals": "-5", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100870 - Disclosure - Stock Incentive and Employee Benefit Plans - Employee Benefit Plan - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansEmployeeBenefitPlanAdditionalInformationDetails", "shortName": "Stock Incentive and Employee Benefit Plans - Employee Benefit Plan - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100880 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_18b251b2-0c16-48e0-9ac4-81b352237497", "decimals": null, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100890 - Disclosure - Commitments and Contingencies - Operating Leases - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Operating Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100900 - Disclosure - Commitments and Contingencies - Supplemental Quantitative Information Related to Leases (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSupplementalQuantitativeInformationRelatedToLeasesDetails", "shortName": "Commitments and Contingencies - Supplemental Quantitative Information Related to Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100910 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Liability Maturities (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails", "shortName": "Commitments and Contingencies - Schedule of Operating Lease Liability Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Liquidity and Going Concern", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLiquidityAndGoingConcern", "shortName": "Liquidity and Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100920 - Disclosure - Income Taxes - Schedule of Loss Before Income Tax By Location (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxByLocationDetails", "shortName": "Income Taxes - Schedule of Loss Before Income Tax By Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100930 - Disclosure - Income Taxes - Schedule of Components of Provision Expense (Benefit) (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails", "shortName": "Income Taxes - Schedule of Components of Provision Expense (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "first": true, "lang": null, "name": "srne:DeferredTaxAssetsOperatingLossAndCreditCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100940 - Disclosure - Income Taxes - Summary of Components of Net Deferred Tax Liabilities and Related Valuation Allowance (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails", "shortName": "Income Taxes - Summary of Components of Net Deferred Tax Liabilities and Related Valuation Allowance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "first": true, "lang": null, "name": "srne:DeferredTaxAssetsOperatingLossAndCreditCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100950 - Disclosure - Income Taxes - Summary of Reconciliation Between Federal Income Tax and Company Provision for Income Taxes (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails", "shortName": "Income Taxes - Summary of Reconciliation Between Federal Income Tax and Company Provision for Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100960 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_4fce743f-cb5a-447c-a0bc-d392ff793f3d", "decimals": "-5", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_3c7fc13a-59d0-4240-a412-aca7ac29b1fc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100970 - Disclosure - Income Taxes - Summary of Reconciliation of Unrecognized Tax Expense (Benefits) (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxExpenseBenefitsDetails", "shortName": "Income Taxes - Summary of Reconciliation of Unrecognized Tax Expense (Benefits) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_59e2e797-f6a7-4f89-8733-5d73dc2a4883", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100980 - Disclosure - Related Party Agreements and Other - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "shortName": "Related Party Agreements and Other - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_36d9c941-8bd1-4307-a73f-c1b49755c71e", "decimals": "-5", "lang": null, "name": "us-gaap:NotesReceivableRelatedParties", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100990 - Disclosure - Segment Information - Additional Information (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetails", "shortName": "Segment Information - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_c7db7172-7558-47c7-bf33-5d9afd5ce6aa", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_Segment", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_52b93e67-04f9-4e29-a750-1edc5e64b4cd", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101000 - Disclosure - Segment Information - Summary of Information by Reportable Segments (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfInformationByReportableSegmentsDetails", "shortName": "Segment Information - Summary of Information by Reportable Segments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_64e44a86-9c9b-476e-9b27-51827bc82745", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "srne-20211231.htm", "contextRef": "C_52b93e67-04f9-4e29-a750-1edc5e64b4cd", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101010 - Disclosure - Quarterly Financial Data (Unaudited) - Schedule of Quarterly Financial Data (Details)", "role": "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureQuarterlyFinancialDataUnauditedScheduleOfQuarterlyFinancialDataDetails", "shortName": "Quarterly Financial Data (Unaudited) - Schedule of Quarterly Financial Data (Details)", "subGroupType": "details", "uniqueAnchor": null } }, "segmentCount": 178, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "verboseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r851", "r852", "r853" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r851", "r852", "r853" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r851", "r852", "r853" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r851", "r852", "r853" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "verboseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r854" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r849" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r848" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsLicenseAgreementWithIcahnSchoolOfMedicineAtMountSinaiAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithACEATherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithPersonalizedStemCellsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithTheTrusteesOfColumbiaUniversityInCityOfNewYorkAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansScilexHoldingCompanyAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r848" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r848" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r862" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r848" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r848" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r848" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r848" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r863" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r851", "r852", "r853" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsLicenseAgreementWithIcahnSchoolOfMedicineAtMountSinaiAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithACEATherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithPersonalizedStemCellsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithTheTrusteesOfColumbiaUniversityInCityOfNewYorkAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansScilexHoldingCompanyAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r847" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r850" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "tradingSymbolItemType" }, "srne_ACEAAcquisitionConsiderationPaidInEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "ACEA acquisition consideration paid in equity.", "label": "A C E A Acquisition Consideration Paid In Equity", "terseLabel": "ACEA acquisition consideration paid in equity" } } }, "localname": "ACEAAcquisitionConsiderationPaidInEquity", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srne_ACEABioHangzhouCompanyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ACEA bio Hangzhou company limited.", "label": "A C E A Bio Hangzhou Company Limited [Member]", "terseLabel": "ACEA Bio" } } }, "localname": "ACEABioHangzhouCompanyLimitedMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_ACEATherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ACEA Therapeutics Inc.", "label": "A C E A Therapeutics Inc [Member]", "terseLabel": "ACEA Therapeutics, Inc" } } }, "localname": "ACEATherapeuticsIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentConsiderationLiabilitiesAreMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3De", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithACEATherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "srne_AardvarkTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aardvark Therapeutics Inc.", "label": "Aardvark Therapeutics Inc [Member]", "terseLabel": "Aardvark" } } }, "localname": "AardvarkTherapeuticsIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_AccountingFirmMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Firm", "label": "Accounting Firm [Member]" } } }, "localname": "AccountingFirmMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "domainItemType" }, "srne_AceaTherapeuticsIncAndSemnurPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ACEA therapeutics, inc and semnur pharmaceuticals, inc.", "label": "ACEA Therapeutics, Inc. and Semnur Pharmaceuticals, Inc [Member]", "terseLabel": "ACEA and Semnur" } } }, "localname": "AceaTherapeuticsIncAndSemnurPharmaceuticalsIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_AcquisitionConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisition Consideration [Member]", "label": "Acquisition Consideration [Member]", "terseLabel": "Acquisition Consideration" } } }, "localname": "AcquisitionConsiderationMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_AcquisitionCostsIncurredButNotYetPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Acquisition Costs Incurred But Not Yet Paid", "label": "Acquisition Costs Incurred But Not Yet Paid", "terseLabel": "Semnur acquisition costs incurred but not paid" } } }, "localname": "AcquisitionCostsIncurredButNotYetPaid", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srne_AcquisitionOfSmartPharmTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisition of SmartPharm Therapeutics, Inc.", "label": "Acquisition Of Smart Pharm Therapeutics Inc [Member]", "terseLabel": "SmartPharm" } } }, "localname": "AcquisitionOfSmartPharmTherapeuticsIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSmartpharmTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "srne_AdjustmentsToAdditionalPaidInCapitalLossOnDebtExtinguishment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments To Additional Paid In Capital, Loss on Debt Extinguishment", "label": "Adjustments To Additional Paid In Capital Loss On Debt Extinguishment", "terseLabel": "Loss on debt extinguishment" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalLossOnDebtExtinguishment", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "srne_AdjustmentstoAdditionalPaidinCapitalWarrantIssuedTermLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to Additional Paid in Capital, Warrant Issued, Term Loan", "label": "Adjustmentsto Additional Paidin Capital Warrant Issued Term Loan", "terseLabel": "Warrants issued in connection with Term Loan Agreement" } } }, "localname": "AdjustmentstoAdditionalPaidinCapitalWarrantIssuedTermLoan", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "srne_AmendedSalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended sales agreement.", "label": "Amended Sales Agreement [Member]", "terseLabel": "Amended Sales Agreement" } } }, "localname": "AmendedSalesAgreementMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_AmountOfCapitalizationToMeetFinalMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of capitalization to meet final milestones.", "label": "Amount Of Capitalization To Meet Final Milestones", "terseLabel": "Amount of capitalization to meet final milestones" } } }, "localname": "AmountOfCapitalizationToMeetFinalMilestones", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_AmountOfCapitalizationToMeetNextThreeMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of capitalization to meet next three milestones.", "label": "Amount Of Capitalization To Meet Next Three Milestones", "terseLabel": "Amount of capitalization to meet next three milestones" } } }, "localname": "AmountOfCapitalizationToMeetNextThreeMilestones", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_AmountOfCapitalizationToMeetNextThreeMilestonesThereafter": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of capitalization to meet next three milestones thereafter.", "label": "Amount Of Capitalization To Meet Next Three Milestones Thereafter", "terseLabel": "Amount of capitalization to meet next three milestones thereafter" } } }, "localname": "AmountOfCapitalizationToMeetNextThreeMilestonesThereafter", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_AmountOfCapitalizationToMeetNextTwoMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of capitalization to meet next two milestones.", "label": "Amount Of Capitalization To Meet Next Two Milestones", "terseLabel": "Amount of capitalization to meet next two milestones" } } }, "localname": "AmountOfCapitalizationToMeetNextTwoMilestones", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_AprilThirteenTwoThousandTwentyOneOptionalRepurchaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "April 13, 2021, optional repurchase.", "label": "April Thirteen Two Thousand Twenty One Optional Repurchase [Member]", "terseLabel": "April Optional Repurchase" } } }, "localname": "AprilThirteenTwoThousandTwentyOneOptionalRepurchaseMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_AspirePurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aspire purchase agreement.", "label": "Aspire Purchase Agreement [Member]", "terseLabel": "Aspire Purchase Agreement" } } }, "localname": "AspirePurchaseAgreementMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAspireTransactionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_AssembledWorkforceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assembled Workforce [Member]", "label": "Assembled Workforce [Member]", "terseLabel": "Assembled workforce" } } }, "localname": "AssembledWorkforceMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srne_AssetAcquisitionConsiderationTransferredGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Gross", "label": "Asset Acquisition Consideration Transferred Gross", "terseLabel": "Cash consideration" } } }, "localname": "AssetAcquisitionConsiderationTransferredGross", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_AssetAcquisitionContingentConsiderationArrangements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Contingent Consideration Arrangements", "label": "Asset Acquisition Contingent Consideration Arrangements", "terseLabel": "Asset acquisition, contingent consideration arrangements" } } }, "localname": "AssetAcquisitionContingentConsiderationArrangements", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_AssetAcquisitionContingentConsiderationArrangementsCumulativeNetSalesThreshold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Contingent Consideration Arrangements, Cumulative Net Sales Threshold", "label": "Asset Acquisition Contingent Consideration Arrangements Cumulative Net Sales Threshold", "terseLabel": "Asset acquisition, contingent consideration arrangements, cumulative net sales threshold" } } }, "localname": "AssetAcquisitionContingentConsiderationArrangementsCumulativeNetSalesThreshold", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Value, High", "label": "Asset Acquisition Contingent Consideration Arrangements Range Of Outcomes Value High", "terseLabel": "Additional cash consideration upon certain milestones" } } }, "localname": "AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_AssetAcquisitionContingentEquityInterestIssuableNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Contingent Equity Interest Issuable, Number Of Shares", "label": "Asset Acquisition Contingent Equity Interest Issuable Number Of Shares", "terseLabel": "Stock consideration value", "verboseLabel": "Stock consideration shares" } } }, "localname": "AssetAcquisitionContingentEquityInterestIssuableNumberOfShares", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAssetPurchaseAgreementWithAardvarkTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSmartpharmTherapeuticsIncAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "srne_AssetAcquisitionContingentEquityInterestIssuableValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset acquisition contingent equity interest issuable value.", "label": "Asset Acquisition Contingent Equity Interest Issuable Value", "terseLabel": "Stock consideration shares value" } } }, "localname": "AssetAcquisitionContingentEquityInterestIssuableValue", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_AssetAcquisitionEligiblePercentageOfEquityInterestAcquiredByRelatedPartyToExchangeShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset acquisition eligible percentage of equity interest acquired by related party to exchange share.", "label": "Asset Acquisition Eligible Percentage Of Equity Interest Acquired By Related Party To Exchange Share", "terseLabel": "Eligible percentage of equity interest acquired by third party to exchange share" } } }, "localname": "AssetAcquisitionEligiblePercentageOfEquityInterestAcquiredByRelatedPartyToExchangeShare", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_AssetAcquisitionEquityInterestIssuedOrIssuablePeriodOfShareExchange": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset acquisition equity interest issued or issuable period of share exchange.", "label": "Asset Acquisition Equity Interest Issued Or Issuable Period Of Share Exchange", "terseLabel": "Share exchange period" } } }, "localname": "AssetAcquisitionEquityInterestIssuedOrIssuablePeriodOfShareExchange", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "srne_AssetAcquisitionEquityInterestIssuedOrIssuableValueAssigned": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Equity Interest Issued Or Issuable, Value Assigned", "label": "Asset Acquisition Equity Interest Issued Or Issuable Value Assigned", "terseLabel": "Stock consideration value" } } }, "localname": "AssetAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_AssetAcquisitionEquityInterestIssuedOrIssuableValueAssignedPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Equity Interest Issued Or Issuable, Value Assigned Per Share", "label": "Asset Acquisition Equity Interest Issued Or Issuable Value Assigned Per Share", "terseLabel": "Stock consideration value per share (usd per share)" } } }, "localname": "AssetAcquisitionEquityInterestIssuedOrIssuableValueAssignedPerShare", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "srne_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfDaysTrailingVolumeWeightedAverageSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset acquisition equity interests issued or issuable number of days trailing volume weighted average share price.", "label": "Asset Acquisition Equity Interests Issued Or Issuable Number Of Days Trailing Volume Weighted Average Share Price", "terseLabel": "Trailing volume weighted average share price, term" } } }, "localname": "AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfDaysTrailingVolumeWeightedAverageSharePrice", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "srne_AssetAcquisitionLiabilitiesAssumed": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Liabilities Assumed", "label": "Asset Acquisition Liabilities Assumed", "terseLabel": "Asset acquisition, liabilities assumed" } } }, "localname": "AssetAcquisitionLiabilitiesAssumed", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_AssetAcquisitionPercentageOfShareAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset acquisition percentage of share acquired.", "label": "Asset Acquisition Percentage Of Share Acquired", "terseLabel": "Percentage of shares acquired" } } }, "localname": "AssetAcquisitionPercentageOfShareAcquired", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_AssetAcquisitionTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Transaction Costs", "label": "Asset Acquisition Transaction Costs", "terseLabel": "Asset acquisition, transaction costs" } } }, "localname": "AssetAcquisitionTransactionCosts", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_AssetPurchaseAgreementWithAardvarkTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset purchase agreement with Aardvark Therapeutics, Inc.", "label": "Asset Purchase Agreement With Aardvark Therapeutics Inc [Member]", "terseLabel": "Asset Purchase Agreement with Aadvark Therapeutics, Inc." } } }, "localname": "AssetPurchaseAgreementWithAardvarkTherapeuticsIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAssetPurchaseAgreementWithAardvarkTherapeuticsIncAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_BDLProductsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BDL Products, Inc", "label": "B D L Products Inc [Member]", "terseLabel": "BDL Products Inc" } } }, "localname": "BDLProductsIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "srne_BRileyCommercialCapitalLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "B. Riley Commercial Capital, LLC.", "label": "B. Riley Commercial Capital, LLC [Member]", "terseLabel": "B. Riley Commercial Capital, LLC" } } }, "localname": "BRileyCommercialCapitalLlcMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_BridgeLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bridge loan agreement.", "label": "Bridge Loan Agreement [Member]", "terseLabel": "Bridge Loan Agreement" } } }, "localname": "BridgeLoanAgreementMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_BusinessCombinationAdditionalConsiderationTransferredSubjectToAchievementOfCertainRegulatoryMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination additional consideration transferred subject to achievement of certain regulatory milestones.", "label": "Business Combination Additional Consideration Transferred subject to achievement of certain regulatory milestones", "terseLabel": "Additional purchase consideration subject to achievement of certain regulatory milestones" } } }, "localname": "BusinessCombinationAdditionalConsiderationTransferredSubjectToAchievementOfCertainRegulatoryMilestones", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_BusinessCombinationConsiderationTransferredAfterAdjusted": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination consideration transferred after adjusted.", "label": "Business Combination Consideration Transferred After Adjusted", "terseLabel": "Purchase consideration after adjusted" } } }, "localname": "BusinessCombinationConsiderationTransferredAfterAdjusted", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_BusinessCombinationMaximumPercentageOfSharesIssuableAsConsiderationOfTotalNumberOfSharesOfCommonStockIssuedAndOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business combination maximum percentage of shares issuable as consideration of total number of shares of common stock issued and outstanding.", "label": "Business combination maximum percentage of shares issuable as consideration of total number of shares of common stock issued and outstanding", "terseLabel": "Business combination maximum percentage of shares issuable as consideration of total number of shares of common stock issued and outstanding" } } }, "localname": "BusinessCombinationMaximumPercentageOfSharesIssuableAsConsiderationOfTotalNumberOfSharesOfCommonStockIssuedAndOutstanding", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_BusinessCombinationNumberOfProductsDevelopedForRoyaltyPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Number Of Products Developed For Royalty Payment", "label": "Business Combination Number Of Products Developed For Royalty Payment", "terseLabel": "Number of products developed for royalty payment" } } }, "localname": "BusinessCombinationNumberOfProductsDevelopedForRoyaltyPayment", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "srne_BusinessCombinationOfAdditionalShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination of Additional Shares", "label": "Business combination of additional shares" } } }, "localname": "BusinessCombinationOfAdditionalShares", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "srne_BusinessCombinationPercentageOfConsiderationPaidInCash": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business combination percentage of consideration paid in cash.", "label": "Business Combination Percentage of Consideration Paid in Cash", "terseLabel": "Percentage of consideration paid in cash" } } }, "localname": "BusinessCombinationPercentageOfConsiderationPaidInCash", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_BusinessCombinationPercentageOfConsiderationPaidInCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business combination percentage of consideration paid in common stock.", "label": "Business combination percentage of consideration paid in common stock", "terseLabel": "Percentage of consideration paid in common stock" } } }, "localname": "BusinessCombinationPercentageOfConsiderationPaidInCommonStock", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_BusinessCombinationUpfrontConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination upfront consideration.", "label": "Business Combination Upfront Consideration", "terseLabel": "Upfront consideration" } } }, "localname": "BusinessCombinationUpfrontConsideration", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_CARgenixHoldingLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CARgenix Holding.", "label": "C A Rgenix Holding L L C [Member]", "terseLabel": "CARgenix Holding LLC" } } }, "localname": "CARgenixHoldingLLCMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_CEOPerformanceAwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CEO performance award.", "label": "C E O Performance Award [Member]", "terseLabel": "C E O Performance Award" } } }, "localname": "CEOPerformanceAwardMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCommonStockReservedForFutureIssuanceAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_CNHFinanceFundILPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "C N H Finance Fund I, L.P.", "label": "C N H Finance Fund I, L.P [Member[", "terseLabel": "C N H Finance Fund I, L.P" } } }, "localname": "CNHFinanceFundILPMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_CapitalizedSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capitalized software member.", "label": "Capitalized software [member]", "terseLabel": "Capitalized software" } } }, "localname": "CapitalizedSoftwareMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srne_CashPurchasePricePercentageOfPrincipalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Purchase Price, Percentage of Principal Amount", "label": "Cash Purchase Price Percentage Of Principal Amount", "terseLabel": "Cash purchase price, percentage of principal amount" } } }, "localname": "CashPurchasePricePercentageOfPrincipalAmount", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_CelularityIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Celularity, Inc.", "label": "Celularity Inc [Member]", "terseLabel": "Celularity" } } }, "localname": "CelularityIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_ChangesToNoncontrollingInterestsFromIncreasedOwnership": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Changes to noncontrolling interests from increased ownership.", "label": "Changes To Noncontrolling Interests From Increased Ownership", "terseLabel": "Changes to noncontrolling interests from increased ownership in Scilex Holding" } } }, "localname": "ChangesToNoncontrollingInterestsFromIncreasedOwnership", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srne_CommonStockReceivedInExchangeForLicense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common stock received in exchange for license.", "label": "Common Stock Received In Exchange For License", "terseLabel": "Conversion of convertible notes" } } }, "localname": "CommonStockReceivedInExchangeForLicense", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srne_CommonStockSharesReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock shares received.", "label": "Common Stock Shares Received", "terseLabel": "Common stock received" } } }, "localname": "CommonStockSharesReceived", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "srne_CommonStockSharesSubjectToTransferRestrictions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock shares subject to transfer restrictions.", "label": "Common Stock Shares Subject To Transfer Restrictions", "terseLabel": "Common stock shares subject to transfer restrictions" } } }, "localname": "CommonStockSharesSubjectToTransferRestrictions", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "srne_CommonStockSharesSubjectToTransferRestrictionsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock shares subject to transfer restrictions description.", "label": "Common Stock Shares Subject To Transfer Restrictions Description", "terseLabel": "Common stock shares subject to transfer restrictions description" } } }, "localname": "CommonStockSharesSubjectToTransferRestrictionsDescription", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srne_ConsultingAgreementWithKimJandaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting agreement with Kim Janda.", "label": "Consulting Agreement With Kim Janda [Member]", "terseLabel": "Consulting agreement with Kim Janda" } } }, "localname": "ConsultingAgreementWithKimJandaMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_ContingentAccelerationFeatureEarlyConditionalLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Acceleration Feature, Early Conditional Loan", "label": "Contingent Acceleration Feature Early Conditional Loan [Member]", "terseLabel": "Early Conditional Loan" } } }, "localname": "ContingentAccelerationFeatureEarlyConditionalLoanMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_ContingentConsiderationCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration, Current", "label": "Contingent Consideration Current [Member]", "terseLabel": "Acquisition consideration payable", "verboseLabel": "Contingent Consideration Current" } } }, "localname": "ContingentConsiderationCurrentMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "srne_ContingentConsiderationNoncurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration, Noncurrent [Member]", "label": "Contingent Consideration Noncurrent [Member]", "terseLabel": "Acquisition consideration payable, non-current", "verboseLabel": "Contingent Consideration Noncurrent" } } }, "localname": "ContingentConsiderationNoncurrentMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "srne_ContingentLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent Liability", "label": "Contingent Liability", "terseLabel": "Contingent liability" } } }, "localname": "ContingentLiability", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_CumulativeNetSalesFiveHundredMillionDollarsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative Net Sales, Five Hundred Million Dollars", "label": "Cumulative Net Sales Five Hundred Million Dollars [Member]", "terseLabel": "Cumulative Net Sales, $500 million" } } }, "localname": "CumulativeNetSalesFiveHundredMillionDollarsMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_CumulativeNetSalesOneHundredMillionDollarsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative Net Sales, One Hundred Million Dollars", "label": "Cumulative Net Sales One Hundred Million Dollars [Member]", "terseLabel": "Cumulative Net Sales, $100 million" } } }, "localname": "CumulativeNetSalesOneHundredMillionDollarsMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_CumulativeNetSalesSevenHundredAndFiftyMillionDollarsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative Net Sales, Seven Hundred And Fifty Million Dollars", "label": "Cumulative Net Sales Seven Hundred And Fifty Million Dollars [Member]", "terseLabel": "Cumulative Net Sales, $750 million" } } }, "localname": "CumulativeNetSalesSevenHundredAndFiftyMillionDollarsMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_CumulativeNetSalesTwoHundredAndFiftyMillionDollarsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative Net Sales, Two Hundred And Fifty Million Dollars", "label": "Cumulative Net Sales Two Hundred And Fifty Million Dollars [Member]", "terseLabel": "Cumulative Net Sales, $250 million" } } }, "localname": "CumulativeNetSalesTwoHundredAndFiftyMillionDollarsMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_CytimmTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cytimm Therapeutics, Inc.", "label": "Cytimm Therapeutics Inc [Member]", "terseLabel": "Cytimm" } } }, "localname": "CytimmTherapeuticsIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_DebtDefaultShortTermDebtInterestRatePerAnnum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt default, short-term debt, interest rate per annum.", "label": "Debt Default, Short-term Debt, Interest Rate per Annum", "terseLabel": "Interest rate per annum at event of default" } } }, "localname": "DebtDefaultShortTermDebtInterestRatePerAnnum", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_DebtInstrumentAdditionalPrincipalPaymentSalesThreshold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Additional Principal Payment, Sales Threshold", "label": "Debt Instrument Additional Principal Payment Sales Threshold", "terseLabel": "Additional principal payments, sales threshold" } } }, "localname": "DebtInstrumentAdditionalPrincipalPaymentSalesThreshold", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_DebtInstrumentAggregatePrincipalPaymentIncreaseIfCumulativeTargetSalesNotMet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Aggregate Principal Payment Increase If Cumulative Target Sales Not Met", "label": "Debt Instrument Aggregate Principal Payment Increase If Cumulative Target Sales Not Met", "terseLabel": "Aggregate principal payment increase amount if cumulative net sales are not met" } } }, "localname": "DebtInstrumentAggregatePrincipalPaymentIncreaseIfCumulativeTargetSalesNotMet", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_DebtInstrumentCollateralFeeAnnualRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Collateral Fee, Annual Rate", "label": "Debt Instrument Collateral Fee Annual Rate", "terseLabel": "Debt instrument collateral fee, annual rate" } } }, "localname": "DebtInstrumentCollateralFeeAnnualRate", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsShortTermLoansAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_DebtInstrumentCovenantMinimumCashEquivalents": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument covenant minimum cash equivalents.", "label": "Debt Instrument Covenant Minimum Cash Equivalents", "terseLabel": "Minimum cash covenant" } } }, "localname": "DebtInstrumentCovenantMinimumCashEquivalents", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_DebtInstrumentDebtDefaultPercentageOfOutstandingPrincipalPayable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Debt Default, Percentage Of Outstanding Principal Payable", "label": "Debt Instrument Debt Default Percentage Of Outstanding Principal Payable", "terseLabel": "Percentage of outstanding payable due upon default" } } }, "localname": "DebtInstrumentDebtDefaultPercentageOfOutstandingPrincipalPayable", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_DebtInstrumentDebtDefaultRightToDeclarePayableOnAllOutstandingPrincipalPercentageOfPrincipalAmountOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Debt Default, Right To Declare Payable On All Outstanding Principal, Percentage Of Principal Amount Outstanding", "label": "Debt Instrument Debt Default Right To Declare Payable On All Outstanding Principal Percentage Of Principal Amount Outstanding", "terseLabel": "Percentage of outstanding principal holders can declare debt payable upon default" } } }, "localname": "DebtInstrumentDebtDefaultRightToDeclarePayableOnAllOutstandingPrincipalPercentageOfPrincipalAmountOutstanding", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_DebtInstrumentEffectiveTerminationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument effective termination date.", "label": "Debt Instrument Effective Termination Date", "terseLabel": "Debt instrument effective termination date" } } }, "localname": "DebtInstrumentEffectiveTerminationDate", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "srne_DebtInstrumentIncreaseToFaceAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument increase to face amount.", "label": "Debt Instrument Increase To Face Amount", "terseLabel": "Increase to aggregate principal amount" } } }, "localname": "DebtInstrumentIncreaseToFaceAmount", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_DebtInstrumentInterestFreePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument, interest free period.", "label": "Debt Instrument Interest Free Period", "terseLabel": "Debt instrument, interest free period" } } }, "localname": "DebtInstrumentInterestFreePeriod", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "srne_DebtInstrumentPaymentPeriodFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Payment, Period Five", "label": "Debt Instrument Payment Period Five [Member]", "terseLabel": "October 1, 2022 - September 30, 2023" } } }, "localname": "DebtInstrumentPaymentPeriodFiveMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_DebtInstrumentPaymentPeriodFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Payment, Period Four", "label": "Debt Instrument Payment Period Four [Member]", "terseLabel": "February 15, 2022" } } }, "localname": "DebtInstrumentPaymentPeriodFourMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_DebtInstrumentPaymentPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Payment, Period One", "label": "Debt Instrument Payment Period One [Member]", "terseLabel": "February 15, 2019 - March 31, 2021" } } }, "localname": "DebtInstrumentPaymentPeriodOneMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_DebtInstrumentPaymentPeriodThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Payment, Period Three", "label": "Debt Instrument Payment Period Three [Member]", "terseLabel": "October 1, 2022 - September 30, 2023" } } }, "localname": "DebtInstrumentPaymentPeriodThreeMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_DebtInstrumentPaymentPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Payment, Period Two", "label": "Debt Instrument Payment Period Two [Member]", "terseLabel": "Market approval by March 31, 2021" } } }, "localname": "DebtInstrumentPaymentPeriodTwoMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_DebtInstrumentPercentageOfPrincipalAmountOutstandingHoldersAcceptanceToReplaceLetterOfCredit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Percentage Of Principal Amount Outstanding Holders Acceptance To Replace Letter Of Credit", "label": "Debt Instrument Percentage Of Principal Amount Outstanding Holders Acceptance To Replace Letter Of Credit", "terseLabel": "Percentage of principal amount outstanding holders need as an acceptance to replace letter of credit" } } }, "localname": "DebtInstrumentPercentageOfPrincipalAmountOutstandingHoldersAcceptanceToReplaceLetterOfCredit", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_DebtInstrumentPrincipalAdjustmentsNoncash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument principal adjustments noncash.", "label": "Debt Instrument Principal Adjustments Noncash", "terseLabel": "Scilex Notes principal increase" } } }, "localname": "DebtInstrumentPrincipalAdjustmentsNoncash", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srne_DebtInstrumentPrincipalIncreaseAdjustments": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument principal increase adjustments.", "label": "Debt Instrument Principal Increase Adjustments", "negatedLabel": "Scilex Notes principal increase", "terseLabel": "Scilex Notes principal increase" } } }, "localname": "DebtInstrumentPrincipalIncreaseAdjustments", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "srne_DebtInstrumentQuarterlyPrincipalPaymentPercentageOfSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Quarterly Principal Payment, Percentage Of Sales", "label": "Debt Instrument Quarterly Principal Payment Percentage Of Sales", "terseLabel": "Quarterly principal payment as a percentage of net sales" } } }, "localname": "DebtInstrumentQuarterlyPrincipalPaymentPercentageOfSales", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_DebtInstrumentRedemptionNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Redemption, Notice Period", "label": "Debt Instrument Redemption Notice Period", "terseLabel": "Period of notice for debt redemption" } } }, "localname": "DebtInstrumentRedemptionNoticePeriod", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "srne_DebtInstrumentReductionToFaceAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument reduction to face amount.", "label": "Debt Instrument Reduction To Face Amount", "terseLabel": "Reduction to aggregate principal amount" } } }, "localname": "DebtInstrumentReductionToFaceAmount", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_DecemberSixteenTwoThousandTwentyAndFebruaryTwelveTwoThousandTwentyOneOptionalRepurchaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December sixteen two thousand twenty and february twelve two thousand twenty one optional repurchase.", "label": "December Sixteen Two Thousand Twenty And February Twelve Two Thousand Twenty One Optional Repurchase [Member]", "terseLabel": "Optional Repurchases" } } }, "localname": "DecemberSixteenTwoThousandTwentyAndFebruaryTwelveTwoThousandTwentyOneOptionalRepurchaseMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_DecemberSixteenTwoThousandTwentyOptionalRepurchaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December 16, 2020 optional repurchase.", "label": "December Sixteen Two Thousand Twenty Optional Repurchase [Member]", "terseLabel": "December Optional Repurchase" } } }, "localname": "DecemberSixteenTwoThousandTwentyOptionalRepurchaseMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_DecemberTwoThousandAndTwentyOneAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December two thousand and twenty one amendment.", "label": "December Two Thousand and Twenty One Amendment [Member]", "terseLabel": "December 2021 Amendment" } } }, "localname": "DecemberTwoThousandAndTwentyOneAmendmentMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_DecemberTwoThousandNineteenWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December Two Thousand Nineteen Warrants", "label": "December Two Thousand Nineteen Warrants [Member]", "terseLabel": "December 2019 Warrants" } } }, "localname": "DecemberTwoThousandNineteenWarrantsMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "srne_DefenseAdvancedResearchProjectsAgencyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defense Advanced Research Projects Agency.", "label": "Defense Advanced Research Projects Agency [Member]", "terseLabel": "DARPA Contract" } } }, "localname": "DefenseAdvancedResearchProjectsAgencyMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_DeferredRentAndOtherPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred rent and other period increase (decrease).", "label": "Deferred Rent And Other Period Increase Decrease", "terseLabel": "Other" } } }, "localname": "DeferredRentAndOtherPeriodIncreaseDecrease", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srne_DeferredTaxAssetsDebtRelatedInterest": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets Debt related interest.", "label": "Deferred Tax Assets Debt Related Interest", "terseLabel": "Debt related interest" } } }, "localname": "DeferredTaxAssetsDebtRelatedInterest", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "srne_DeferredTaxAssetsOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Operating Lease Liabilities", "label": "Deferred Tax Assets Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "DeferredTaxAssetsOperatingLeaseLiabilities", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "srne_DeferredTaxAssetsOperatingLossAndCreditCarryforwards": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets operating loss and credit carry forwards.", "label": "Deferred Tax Assets Operating Loss And Credit Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossAndCreditCarryforwards", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "srne_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Operating Lease Right-Of-Use Assets", "label": "Deferred Tax Liabilities Operating Lease Right Of Use Assets", "negatedLabel": "Operating lease right-of-use assets" } } }, "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "srne_DerivativeFinancialInstrumentsLiabilitiesCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Financial Instruments, Liabilities, Current", "label": "Derivative Financial Instruments Liabilities Current [Member]", "terseLabel": "Derivative liabilities" } } }, "localname": "DerivativeFinancialInstrumentsLiabilitiesCurrentMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "srne_DerivativeFinancialInstrumentsLiabilitiesNoncurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Financial Instruments, Liabilities, Noncurrent", "label": "Derivative Financial Instruments Liabilities Noncurrent [Member]", "terseLabel": "Derivative liabilities - non-current" } } }, "localname": "DerivativeFinancialInstrumentsLiabilitiesNoncurrentMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "srne_DescriptionOfBusinessPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of business.", "label": "Description Of Business Policy [Text Block]", "terseLabel": "Description of Business" } } }, "localname": "DescriptionOfBusinessPolicyTextBlock", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "srne_DevelopmentAndManufacturingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development and manufacturing.", "label": "Development And Manufacturing [Member]", "terseLabel": "Development and manufacturing expenses" } } }, "localname": "DevelopmentAndManufacturingMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_DeverraTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deverra Therapeutics Inc.", "label": "Deverra Therapeutics Inc [Member]", "terseLabel": "Deverra Therapeutics Inc", "verboseLabel": "Deverra" } } }, "localname": "DeverraTherapeuticsIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_DistributionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distribution Agreement", "label": "Distribution Agreement [Member]", "terseLabel": "Distribution Agreement" } } }, "localname": "DistributionAgreementMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityEquityDistributionAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_EffectiveDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective date.", "label": "Effective Date", "terseLabel": "Effective date" } } }, "localname": "EffectiveDate", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "srne_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Debt Discount, Amount", "label": "Effective Income Tax Rate Reconciliation Debt Discount Amount", "terseLabel": "Debt discount and interest limitation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDebtDiscountAmount", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "srne_ElsieBiotechnologiesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Elsie Biotechnologies Inc.", "label": "Elsie Biotechnologies Inc [Member]", "terseLabel": "Elsie Biotechnologies Inc", "verboseLabel": "Elsie" } } }, "localname": "ElsieBiotechnologiesIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_EquityCompensationPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity compensation plans.", "label": "Equity Compensation Plans [Member]", "terseLabel": "Equity Compensation Plans" } } }, "localname": "EquityCompensationPlansMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "srne_EquityMethodInvestmentVotingInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "equity method investment voting interest.", "label": "Equity Method Investment Voting Interest", "terseLabel": "Equity method investment ownership percentage" } } }, "localname": "EquityMethodInvestmentVotingInterest", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantstemAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_FebruaryTwelveTwoThousandTwentyOneOptionalRepurchaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "February 12, 2021, optional repurchase.", "label": "February Twelve Two Thousand Twenty One Optional Repurchase [Member]", "terseLabel": "February Optional Repurchase" } } }, "localname": "FebruaryTwelveTwoThousandTwentyOneOptionalRepurchaseMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_FirstCommercialSalePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First commercial sale period.", "label": "First Commercial Sale Period", "terseLabel": "First commercial sale period" } } }, "localname": "FirstCommercialSalePeriod", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "srne_FirstMarketCapitalizationMilestoneAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "First market capitalization milestone amount.", "label": "First Market Capitalization Milestone Amount", "terseLabel": "First market capitalization milestone amount" } } }, "localname": "FirstMarketCapitalizationMilestoneAmount", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_GainLossOnContingentConsideration": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) On Contingent Consideration", "label": "Gain (Loss) On Contingent Consideration", "terseLabel": "Loss (gain) on contingent consideration" } } }, "localname": "GainLossOnContingentConsideration", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "srne_GainLossOnContingentLiabilitiesAndAcquisitionConsiderationPayable": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gain Loss On Contingent Liabilities And Acquisition Consideration Payable", "label": "Gain Loss On Contingent Liabilities And Acquisition Consideration Payable", "terseLabel": "Loss (gain) on contingent liabilities and acquisition consideration payable" } } }, "localname": "GainLossOnContingentLiabilitiesAndAcquisitionConsiderationPayable", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srne_GoodwillAndIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill and intangible assets.", "label": "Goodwill And Intangible Assets [Line Items]", "terseLabel": "Goodwill And Intangible Assets [Line Items]" } } }, "localname": "GoodwillAndIntangibleAssetsLineItems", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srne_GoodwillAndIntangibleAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill and intangible assets.", "label": "Goodwill And Intangible Assets [Table]", "terseLabel": "Goodwill And Intangible Assets [Table]" } } }, "localname": "GoodwillAndIntangibleAssetsTable", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srne_HangzhouACEAPharmaceuticalResearchCompanyLimitedAndZhejiangACEAPharmaceuticalCompanyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hangzhou ACEA pharmaceutical research company limited and Zhejiang ACEA pharmaceutical company limited.", "label": "Hangzhou A C E A Pharmaceutical Research Company Limited And Zhejiang A C E A Pharmaceutical Company Limited [Member]", "terseLabel": "ACEA Hangzhou and ACEA Zhejiang" } } }, "localname": "HangzhouACEAPharmaceuticalResearchCompanyLimitedAndZhejiangACEAPharmaceuticalCompanyLimitedMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_HangzhouACEAPharmaceuticalResearchCompanyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hangzhou ACEA pharmaceutical research company limited.", "label": "Hangzhou A C E A Pharmaceutical Research Company Limited [Member]", "terseLabel": "ACEA Hangzhou" } } }, "localname": "HangzhouACEAPharmaceuticalResearchCompanyLimitedMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_HcpLifeScienceReitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HCP Life Science REIT [Member]", "label": "HCP Life Science REIT [Member]", "terseLabel": "HCP Life Science REIT" } } }, "localname": "HcpLifeScienceReitMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_IcahnSchoolOfMedicineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Icahn school of medicine.", "label": "Icahn School of Medicine [Member]", "terseLabel": "Icahn School of Medicine" } } }, "localname": "IcahnSchoolOfMedicineMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsLicenseAgreementWithIcahnSchoolOfMedicineAtMountSinaiAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_IfLetterOfCreditIsDrawnOnMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "If Letter of Credit is Drawn On.", "label": "If Letter Of Credit Is Drawn On [Member]", "terseLabel": "If Letter of Credit is Drawn On" } } }, "localname": "IfLetterOfCreditIsDrawnOnMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_IfScilexDoesNotReceiveMarketingApprovalLetterOnOrPriorToJulyOneTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "If Scilex Does Not Receive Marketing Approval Letter On or Prior to July 1, 2023.", "label": "If Scilex Does Not Receive Marketing Approval Letter On Or Prior To July One Two Thousand Twenty Three [Member]", "terseLabel": "If Scilex Does Not Receive Marketing Approval Letter On or Prior to July 1, 2023" } } }, "localname": "IfScilexDoesNotReceiveMarketingApprovalLetterOnOrPriorToJulyOneTwoThousandTwentyThreeMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_ImmuneOnciaTherapeuticsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ImmuneOncia Therapeutics, LLC", "label": "Immune Oncia Therapeutics L L C [Member]", "terseLabel": "ImmuneOncia Therapeutics, LLC" } } }, "localname": "ImmuneOnciaTherapeuticsLLCMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_ImmunityBioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Immunity Bio.", "label": "Immunity Bio [Member]", "terseLabel": "ImmunityBio" } } }, "localname": "ImmunityBioMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_IncomeTaxLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income tax.", "label": "Income Tax [Line Items]", "terseLabel": "Income Tax [Line Items]" } } }, "localname": "IncomeTaxLineItems", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srne_IncomeTaxReconciliationAcquisitionRelatedCharges": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation acquisition related charges.", "label": "Income Tax Reconciliation Acquisition Related Charges", "terseLabel": "Acquisition related charges" } } }, "localname": "IncomeTaxReconciliationAcquisitionRelatedCharges", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "srne_IncomeTaxReconciliationIncomeTaxCreditsAndIncentives": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation income tax credits and incentives.", "label": "Income Tax Reconciliation Income Tax Credits And Incentives", "negatedLabel": "Income tax credits and incentives" } } }, "localname": "IncomeTaxReconciliationIncomeTaxCreditsAndIncentives", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "srne_IncomeTaxTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income tax.", "label": "Income Tax [Table]", "terseLabel": "Income Tax [Table]" } } }, "localname": "IncomeTaxTable", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srne_IncomeTaxesAndInterestPaidNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes and interest paid net.", "label": "Income Taxes And Interest Paid Net [Abstract]", "terseLabel": "Cash paid during the period for:" } } }, "localname": "IncomeTaxesAndInterestPaidNetAbstract", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "srne_InternallyDevelopedSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally Developed Software.", "label": "Internally Developed Software [Member]", "terseLabel": "Internally developed software" } } }, "localname": "InternallyDevelopedSoftwareMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srne_ItochuChemicalFrontierCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Itochu chemical frontier corporation.", "label": "Itochu Chemical Frontier Corporation [Member]", "terseLabel": "Itochu" } } }, "localname": "ItochuChemicalFrontierCorporationMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_June2018WarrantsAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "June 2018 Warrants, Amendment [Member]", "label": "June2018 Warrants Amendment [Member]", "terseLabel": "June 2018 Warrants, Amendment" } } }, "localname": "June2018WarrantsAmendmentMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "srne_KimberlyClarkSofusaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kimberly Clark Sofusa.", "label": "Kimberly Clark Sofusa [Member]", "terseLabel": "Sofusa" } } }, "localname": "KimberlyClarkSofusaMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_LeaseCommencementYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Commencement year", "label": "Lease Commencement year", "terseLabel": "Lease commencement year" } } }, "localname": "LeaseCommencementYear", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "srne_LeaseCommencementYearAndMonth": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease commencement year and month.", "label": "Lease Commencement Year and Month", "terseLabel": "Lease commencement year and month" } } }, "localname": "LeaseCommencementYearAndMonth", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "srne_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement.", "label": "License Agreement [Member]", "terseLabel": "License Agreement" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsLicenseAgreementWithIcahnSchoolOfMedicineAtMountSinaiAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithACEATherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithPersonalizedStemCellsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithTheTrusteesOfColumbiaUniversityInCityOfNewYorkAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_LiquidityDisclosurePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liquidity Disclosure.", "label": "Liquidity Disclosure Policy Policy [Text Block]", "terseLabel": "Liquidity and Going Concern" } } }, "localname": "LiquidityDisclosurePolicyPolicyTextBlock", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "srne_LljSorrentoIndustrialLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LLJ Sorrento Industrial LLC", "label": "LLJ Sorrento Industrial LLC [Member]", "terseLabel": "LLJ Sorrento Industrial LLC" } } }, "localname": "LljSorrentoIndustrialLlcMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_LongTermDebtMaturitiesRepaymentsOfPrincipalAmount": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long term debt maturities repayments of principal amount.", "label": "Long Term Debt Maturities Repayments Of Principal Amount", "totalLabel": "Total future minimum payments" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAmount", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "srne_LossContingencyDamagesSoughtValueToRestoreEquityMethodInvestment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Damages Sought, Value, To Restore Equity Method Investment", "label": "Loss Contingency Damages Sought Value To Restore Equity Method Investment", "terseLabel": "Damages sought to restore equity method investment" } } }, "localname": "LossContingencyDamagesSoughtValueToRestoreEquityMethodInvestment", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_March2018NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2018 Notes [Member]", "label": "March2018 Notes [Member]", "terseLabel": "March 2018 Notes" } } }, "localname": "March2018NotesMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_March2018WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2018 Warrant [Member]", "label": "March2018 Warrant [Member]", "terseLabel": "March 2018 Warrant" } } }, "localname": "March2018WarrantMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_MarketCapitalizationToFullyVestInAwardIncrease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Market capitalization to fully vest in award increase.", "label": "Market Capitalization To Fully Vest In Award Increase", "terseLabel": "Market capitalization to fully vest in award increase" } } }, "localname": "MarketCapitalizationToFullyVestInAwardIncrease", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_MarketableSecuritiesRemainingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable securities, remaining shares.", "label": "Marketable Securities, Remaining Shares", "terseLabel": "Remaining shares" } } }, "localname": "MarketableSecuritiesRemainingShares", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "srne_MarketableSecuritiesSharesSold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable securities shares sold.", "label": "Marketable Securities Shares Sold", "terseLabel": "Marketable investments shares sold" } } }, "localname": "MarketableSecuritiesSharesSold", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "srne_MaximumAmountForDevelopmentThroughPhaseIIClinicalStudiesOfGeneEncodedAntibody": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum amount for development through Phase II Clinical Studies of Gene-encoded antibody.", "label": "Maximum Amount For Development Through Phase I I Clinical Studies Of Gene Encoded Antibody", "terseLabel": "Maximum amount for development through Phase II Clinical Studies of Gene-encoded antibody" } } }, "localname": "MaximumAmountForDevelopmentThroughPhaseIIClinicalStudiesOfGeneEncodedAntibody", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_MayoFoundationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mayo Foundation.", "label": "Mayo Foundation [Member]", "terseLabel": "Mayo" } } }, "localname": "MayoFoundationMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_MembershipInterestPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Membership interest purchase agreement.", "label": "Membership Interest Purchase Agreement [Member]", "terseLabel": "Membership interest purchase agreement" } } }, "localname": "MembershipInterestPurchaseAgreementMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_MilestonesAchievementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestones Achievement [Member]", "label": "Milestones Achievement [Member]", "terseLabel": "Milestones Achievement" } } }, "localname": "MilestonesAchievementMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_MinimumAnnualRoyaltyPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Minimum annual royalty payments.", "label": "Minimum Annual Royalty Payments", "terseLabel": "Minimum annual royalty payments" } } }, "localname": "MinimumAnnualRoyaltyPayments", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithTheTrusteesOfColumbiaUniversityInCityOfNewYorkAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_MinorityInterestChangesDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minority interest, changes during period.", "label": "Minority Interest Changes During Period", "terseLabel": "Changes to noncontrolling interests from increased ownership in Scilex Holding" } } }, "localname": "MinorityInterestChangesDuringPeriod", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "srne_MountSinaiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mount Sinai.", "label": "Mount Sinai [Member]", "terseLabel": "Mount Sinai" } } }, "localname": "MountSinaiMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsLicenseAgreementWithIcahnSchoolOfMedicineAtMountSinaiAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_NANTibodyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NANTibody.", "label": "N A N Tibody [Member]", "terseLabel": "NANTibody", "verboseLabel": "NANTibody" } } }, "localname": "NANTibodyMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_NantCancerStemLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nant cancer stem LLC.", "label": "Nant Cancer Stem L L C [Member]", "terseLabel": "Nant Cancer Stem LLC" } } }, "localname": "NantCancerStemLLCMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantstemAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_NantCellIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nant cell, Inc.", "label": "Nant Cell Inc [Member]", "terseLabel": "Nant Cell Inc" } } }, "localname": "NantCellIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_NantCellMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nant cell.", "label": "Nant Cell [Member]", "terseLabel": "Nant Cell Inc" } } }, "localname": "NantCellMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_NantKwestIncAndImmunityBioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NantKwest, Inc. and ImmunityBio.", "label": "Nant Kwest Inc And Immunity Bio [Member]", "terseLabel": "NantKwest, Inc. and ImmunityBio" } } }, "localname": "NantKwestIncAndImmunityBioMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_NantPharmaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NantPharma .", "label": "Nant Pharma [Member]", "terseLabel": "Nant Pharma" } } }, "localname": "NantPharmaMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_NetSalesLessThanSpecifiedThresholdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Sales Less Than Specified Threshold [Member]", "label": "Net Sales Less Than Specified Threshold [Member]", "terseLabel": "Net Sales from Issue Date to December 31, 2021 Less than Specified Threshold" } } }, "localname": "NetSalesLessThanSpecifiedThresholdMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_NewDrugApplicationFirstApprovalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Drug Application, First Approval", "label": "New Drug Application First Approval [Member]", "terseLabel": "New Drug Application, First Approval" } } }, "localname": "NewDrugApplicationFirstApprovalMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_NoncashOrPartNoncashAcquisitionValueOfEquityAssumed": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash or part noncash acquisition value of equity assumed.", "label": "Noncash Or Part Noncash Acquisition Value Of Equity Assumed", "terseLabel": "Acquisition consideration paid in equity" } } }, "localname": "NoncashOrPartNoncashAcquisitionValueOfEquityAssumed", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srne_NotesReceivableMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes Receivable Maturity Period", "label": "Notes Receivable Maturity Period", "terseLabel": "Promissory note maturity period" } } }, "localname": "NotesReceivableMaturityPeriod", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "srne_NumberOfBusinessDaysAdvanceNotice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of business days advance notice.", "label": "Number Of Business Days Advance Notice", "terseLabel": "Number of business days advance notice" } } }, "localname": "NumberOfBusinessDaysAdvanceNotice", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "srne_NumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of tranches.", "label": "Number Of Tranches", "terseLabel": "Number of tranches" } } }, "localname": "NumberOfTranches", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "srne_NumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Numerator", "label": "Numerator [Abstract]", "terseLabel": "Numerator" } } }, "localname": "NumeratorAbstract", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareReconciliationOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "srne_OaktreeCapitalManagementLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Oaktree Capital Management, L.P. [Member]", "label": "Oaktree Capital Management L P [Member]", "terseLabel": "Oaktree Capital Management, L.P." } } }, "localname": "OaktreeCapitalManagementLPMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails" ], "xbrltype": "domainItemType" }, "srne_OaktreeTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Oaktree Term Loan [Member]", "label": "Oaktree Term Loan [Member]", "terseLabel": "Oaktree Term Loan" } } }, "localname": "OaktreeTermLoanMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "srne_OperatingLeaseRightOfUseAssetAmortization": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Right-Of-Use Asset, Amortization", "label": "Operating Lease Right Of Use Asset Amortization", "terseLabel": "Non-cash operating lease cost" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortization", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srne_OperatingLossCarryforwardsExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards expiration year.", "label": "Operating Loss Carryforwards Expiration Year", "terseLabel": "Net operating loss carryforward, expiration year" } } }, "localname": "OperatingLossCarryforwardsExpirationYear", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "srne_OptionToPurchaseCommonStockPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option to purchase common stock period.", "label": "Option To Purchase Common Stock Period", "terseLabel": "Option to purchase common stock period" } } }, "localname": "OptionToPurchaseCommonStockPeriod", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "srne_OtherAcquisitionsAndInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other acquisitions and investments.", "label": "Other Acquisitions And Investments [Member]", "terseLabel": "Other Acquisitions and Investments" } } }, "localname": "OtherAcquisitionsAndInvestmentsMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "srne_OtherAcquisitionsLicenseAgreementsAndInvestmentsConsiderationPaidInEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other acquisitions license agreements and investments consideration paid in equity.", "label": "Other Acquisitions License Agreements and Investments Consideration Paid in Equity", "terseLabel": "Other acquisitions, license agreements and investments consideration paid in equity" } } }, "localname": "OtherAcquisitionsLicenseAgreementsAndInvestmentsConsiderationPaidInEquity", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srne_OtherChangesToNoncontrollingInterests": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other changes to noncontrolling interests", "label": "Other changes to noncontrolling interests" } } }, "localname": "OtherChangesToNoncontrollingInterests", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "srne_OtherLoanForgiveness": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other loan forgiveness.", "label": "Other Loan Forgiveness", "terseLabel": "Other loan forgiveness" } } }, "localname": "OtherLoanForgiveness", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srne_OtherProductRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other product revenue.", "label": "Other Product Revenue [Member]", "terseLabel": "Other product Revenue" } } }, "localname": "OtherProductRevenueMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesScheduleOfRevenuesByCategoryDetails" ], "xbrltype": "domainItemType" }, "srne_OtherServiceRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other service revenue.", "label": "Other Service Revenue [Member]", "terseLabel": "Other Service Revenue" } } }, "localname": "OtherServiceRevenueMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesScheduleOfRevenuesByCategoryDetails" ], "xbrltype": "domainItemType" }, "srne_PartnersCapitalAccountUnitPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Partners capital account unit period increase decrease.", "label": "Partners Capital Account Unit Period Increase Decrease", "terseLabel": "Changes to noncontrolling interests from increased ownership in Scilex Holding (in shares)" } } }, "localname": "PartnersCapitalAccountUnitPeriodIncreaseDecrease", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "srne_PaymentNotesAttributedToAccretedInterestRelatedToDebtDiscount": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment notes attributed to accreted interest related to the debt discount.", "label": "Payment Notes Attributed To Accreted Interest Related To Debt Discount", "negatedLabel": "Payment on Scilex Notes attributed to accreted interest related to the debt discount" } } }, "localname": "PaymentNotesAttributedToAccretedInterestRelatedToDebtDiscount", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srne_PaymentsForAssetAcquisitions": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Asset Acquisitions", "label": "Payments For Asset Acquisitions", "negatedLabel": "Purchase of assets related to Semnur, net of cash acquired" } } }, "localname": "PaymentsForAssetAcquisitions", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srne_PaymentsRelatedToShareExchange": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments related to share exchange.", "label": "Payments Related To Share Exchange", "negatedLabel": "Payments related to Semnur Share Exchange" } } }, "localname": "PaymentsRelatedToShareExchange", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srne_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to acquire equity securities without readily determinable fair value.", "label": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value", "terseLabel": "Payments to acquire equity investment" } } }, "localname": "PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_PercentageOfAnnualNetSalesOfRoyaltyBearingProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of annual net sales on royalty bearing products.", "label": "Percentage Of Annual Net Sales Of Royalty Bearing Products", "terseLabel": "Percentage of annual net sales on royalty bearing products" } } }, "localname": "PercentageOfAnnualNetSalesOfRoyaltyBearingProducts", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_PercentageOfBusinessAcquisition": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of business acquisition.", "label": "Percentage Of Business Acquisition", "terseLabel": "Percentage of business acquisition" } } }, "localname": "PercentageOfBusinessAcquisition", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_PercentageOfConsiderationDepositedIntoEscrowAccount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of consideration deposited into escrow account.", "label": "Percentage of consideration deposited into escrow account", "terseLabel": "Percentage of consideration deposited into escrow account" } } }, "localname": "PercentageOfConsiderationDepositedIntoEscrowAccount", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_PercentageOfMinimumThresholdNetSalesToTargetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of minimum threshold net sales to target sales.", "label": "Percentage Of Minimum Threshold Net Sales to Target Sales", "terseLabel": "Percentage of net sales to predetermined threshold target sales" } } }, "localname": "PercentageOfMinimumThresholdNetSalesToTargetSales", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_PercentageOfOutstandingCommonStockHeld": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of outstanding common stock held.", "label": "Percentage Of Outstanding Common Stock Held", "terseLabel": "Percentage of outstanding common stock held" } } }, "localname": "PercentageOfOutstandingCommonStockHeld", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_PercentageOfPremiumToClosingSalesPriceOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of premium to closing sales price of common stock.", "label": "Percentage Of Premium To Closing Sales Price Of Common Stock", "terseLabel": "Percentage of premium to closing sales price of common stock" } } }, "localname": "PercentageOfPremiumToClosingSalesPriceOfCommonStock", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_PercentageOfPrincipalAmountToBePaidAsUpfrontFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount to be paid as upfront fee.", "label": "Percentage of Principal Amount to be paid as Upfront Fee", "terseLabel": "Percentage of principal amount to be paid as upfront fee" } } }, "localname": "PercentageOfPrincipalAmountToBePaidAsUpfrontFee", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_PercentageOfSharesOwnedByBoardMemberOfRelatedParty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares owned by board member of related party.", "label": "Percentage Of Shares Owned By Board Member Of Related Party", "terseLabel": "Percentage of shares owned by board member" } } }, "localname": "PercentageOfSharesOwnedByBoardMemberOfRelatedParty", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_PercentageOfSharesOwnedByDirectorOfRelatedParty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares owned by director of related party.", "label": "Percentage Of Shares Owned By Director Of Related Party", "terseLabel": "Percentage of shares owned by the director and chairperson" } } }, "localname": "PercentageOfSharesOwnedByDirectorOfRelatedParty", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_PercentageOfUpfrontPaymentOrMilestonePaymentComprisedOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of upfront payment or milestone payment comprised of common stock.", "label": "Percentage Of Upfront Payment Or Milestone Payment Comprised Of Common Stock", "terseLabel": "Percentage of upfront payment or milestone payment comprised of common stock" } } }, "localname": "PercentageOfUpfrontPaymentOrMilestonePaymentComprisedOfCommonStock", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithACEATherapeuticsIncAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_PersonalizedStemCellsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Personalized Stem Cells, Inc.", "label": "Personalized Stem Cells Inc [Member]", "terseLabel": "Personalized Stem Cells, Inc" } } }, "localname": "PersonalizedStemCellsIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithPersonalizedStemCellsIncAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_PrincipalAmountToBePurchased": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Principal amount to be purchased.", "label": "Principal Amount To Be Purchased", "terseLabel": "Principal amount to be purchased" } } }, "localname": "PrincipalAmountToBePurchased", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_PrivatePlacementSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private placement shares.", "label": "Private Placement Shares [Member]", "terseLabel": "Private Placement Shares" } } }, "localname": "PrivatePlacementSharesMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_ProceedsFromIssuanceOfSeniorLongTermDebtNetOfIssuanceCostsAndFundingOfReserveAndCollateral": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of senior long term debt net of issuance costs and funding of reserve and collateral.", "label": "Proceeds From Issuance Of Senior Long Term Debt Net Of Issuance Costs And Funding Of Reserve And Collateral", "terseLabel": "Net proceeds after deducting offering expenses and funding reserves and collateral" } } }, "localname": "ProceedsFromIssuanceOfSeniorLongTermDebtNetOfIssuanceCostsAndFundingOfReserveAndCollateral", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory note.", "label": "Promissory Note [Member]", "terseLabel": "Promissory Note" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_PublicOfferingOfCommonStockAndWarrants2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Offering Of Common Stock And Warrants 2019", "label": "Public Offering Of Common Stock And Warrants2019 [Member]", "terseLabel": "Public Offering Of Common Stock And Warrants 2019" } } }, "localname": "PublicOfferingOfCommonStockAndWarrants2019Member", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "srne_PublicPlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public placement.", "label": "Public Placement [Member]", "terseLabel": "Public Placement" } } }, "localname": "PublicPlacementMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "srne_PublicStockOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Stock Offering [Member]", "label": "Public Stock Offering [Member]", "terseLabel": "Public Stock Offering" } } }, "localname": "PublicStockOfferingMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity2019PublicOfferingOfCommonStockAndWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_PulsarTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pulsar Therapeutics, Inc.", "label": "Pulsar Therapeutics Inc [Member]", "terseLabel": "Pulsar" } } }, "localname": "PulsarTherapeuticsIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_PurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase Agreement.", "label": "Purchase Agreement [Member]", "terseLabel": "Purchase Agreement" } } }, "localname": "PurchaseAgreementMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockPurchaseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_PurchasePricePercentageOfPrincipalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price percentage of principal amount.", "label": "Purchase Price Percentage Of Principal Amount", "terseLabel": "Purchase price, percentage of principal amount" } } }, "localname": "PurchasePricePercentageOfPrincipalAmount", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_ReceiveSharesOfCommonStockForEachOutstandingShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Receive shares of common stock for each outstanding share.", "label": "Receive Shares Of Common Stock For Each Outstanding Share", "terseLabel": "Receive shares of common stock for each outstanding share" } } }, "localname": "ReceiveSharesOfCommonStockForEachOutstandingShare", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "srne_RegisteredDirectOffering2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Registered Direct Offering 2019", "label": "Registered Direct Offering2019 [Member]", "terseLabel": "Registered Direct Offering 2019" } } }, "localname": "RegisteredDirectOffering2019Member", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity2019RegisteredDirectOfferingAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "srne_RelatedPartyAdvisoryServicesOneTimeFeePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Related party advisory services onetime fee payable.", "label": "Related Party Advisory Services One Time Fee Payable", "terseLabel": "Advisory services one-time fee payable per annum" } } }, "localname": "RelatedPartyAdvisoryServicesOneTimeFeePayable", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_RelatedPartyAdvisoryServicesOneTimeFeePayableDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related party advisory services one time fee payable date.", "label": "Related Party Advisory Services One Time Fee Payable Date", "terseLabel": "Advisory services one-time fee payable date" } } }, "localname": "RelatedPartyAdvisoryServicesOneTimeFeePayableDate", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "srne_RelatedPartyAdvisoryServicesOneTimeFeePayablePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related party advisory services one-time fee payable period.", "label": "Related Party Advisory Services One Time Fee Payable Period", "terseLabel": "Advisory services one-time fee payable period" } } }, "localname": "RelatedPartyAdvisoryServicesOneTimeFeePayablePeriod", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "srne_ReleaseOfRestrictedFundsHeldInReserveAndCollateralAccount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Release of restricted funds held in reserve and collateral account.", "label": "Release Of Restricted Funds Held In Reserve And Collateral Account", "terseLabel": "Release of restricted funds held in reserve and collateral account" } } }, "localname": "ReleaseOfRestrictedFundsHeldInReserveAndCollateralAccount", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_ResearchAndDevelopmentInProcessAndImpairmentOfIntangibleAssetsFiniteLived": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research And Development In Process And Impairment Of Intangible Assets, Finite-Lived", "label": "Research And Development In Process And Impairment Of Intangible Assets Finite Lived", "terseLabel": "Acquired in-process research and development" } } }, "localname": "ResearchAndDevelopmentInProcessAndImpairmentOfIntangibleAssetsFiniteLived", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "srne_RestrictedCashMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Cash [Member]", "label": "Restricted Cash [Member]", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "srne_RestrictedSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted shares.", "label": "Restricted Shares [Member]", "terseLabel": "Restricted Shares" } } }, "localname": "RestrictedSharesMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_RevenuePerformanceObligationSatisfiedOverTimePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue, Performance Obligation Satisfied Over Time, Period", "label": "Revenue Performance Obligation Satisfied Over Time Period", "terseLabel": "Estimated license contract term based on expected life of patent" } } }, "localname": "RevenuePerformanceObligationSatisfiedOverTimePeriod", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "srne_RevenueRemainingPerformanceObligationAmountExpectedToBeRecognizedInTheNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue, Remaining Performance Obligation, Amount Expected To Be Recognized In The Next Twelve Months", "label": "Revenue Remaining Performance Obligation Amount Expected To Be Recognized In The Next Twelve Months", "terseLabel": "Remaining performance obligation expected to be recognized in the next twelve months" } } }, "localname": "RevenueRemainingPerformanceObligationAmountExpectedToBeRecognizedInTheNextTwelveMonths", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_RevolvingLoanFacilityIndebtedness": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revolving loan facility indebtedness.", "label": "Revolving Loan Facility Indebtedness", "terseLabel": "Indebtedness in connection with an accounts receivable revolving loan facility" } } }, "localname": "RevolvingLoanFacilityIndebtedness", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_RoyaltyAndLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty And License [Member]", "label": "Royalty And License [Member]", "terseLabel": "Royalty And License" } } }, "localname": "RoyaltyAndLicenseMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_RoyaltyPaymentsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Payments, Percent", "label": "Royalty Payments Percent", "terseLabel": "Royalty payments percent" } } }, "localname": "RoyaltyPaymentsPercent", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_RoyaltyReceivableAsPercentageOnNetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty receivable as percentage on net sales.", "label": "Royalty Receivable As Percentage On Net Sales", "terseLabel": "Royalty rate percent of net sales" } } }, "localname": "RoyaltyReceivableAsPercentageOnNetSales", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_SaleAndServiceDrugandReagentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale And Service, Drug and Reagents", "label": "Sale And Service Drugand Reagents [Member]", "terseLabel": "Sale And Service, Drug and Reagents" } } }, "localname": "SaleAndServiceDrugandReagentsMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_SaleAndServiceJointDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale And Service, Joint Development [Member]", "label": "Sale And Service Joint Development [Member]", "terseLabel": "Sale And Service, Joint Development" } } }, "localname": "SaleAndServiceJointDevelopmentMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_SaleOfStockMaximumAmountOfSharesAuthorizedToBeSold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sale of Stock, Maximum Amount Of Shares Authorized To Be Sold", "label": "Sale Of Stock Maximum Amount Of Shares Authorized To Be Sold", "terseLabel": "Potential proceeds from issuance, public offering, maximum" } } }, "localname": "SaleOfStockMaximumAmountOfSharesAuthorizedToBeSold", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAspireTransactionAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockPurchaseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_SaleOfStockSalesAgentCommissionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Sales Agent Commission Percentage", "label": "Sale Of Stock Sales Agent Commission Percentage", "terseLabel": "Sales agent commission percentage" } } }, "localname": "SaleOfStockSalesAgentCommissionPercentage", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_SalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales Agreement.", "label": "Sales Agreement [Member]", "terseLabel": "Sales Agreement" } } }, "localname": "SalesAgreementMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_ScilexHoldingCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Scilex Holding Company [Member]", "label": "Scilex Holding Company [Member]", "terseLabel": "Scilex Holding Company" } } }, "localname": "ScilexHoldingCompanyMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansScilexHoldingCompanyAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_ScilexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Scilex [Member]", "label": "Scilex [Member]", "terseLabel": "Scilex" } } }, "localname": "ScilexMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfInformationByReportableSegmentsDetails" ], "xbrltype": "domainItemType" }, "srne_ScilexPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Scilex Pharmaceuticals, Inc.", "label": "Scilex Pharmaceuticals Inc [Member]", "terseLabel": "Scilex Pharmaceuticals, Inc" } } }, "localname": "ScilexPharmaceuticalsIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "srne_ScilexPharmaceuticalsIncProductSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Scilex Pharmaceuticals Inc. product sales.", "label": "Scilex Pharmaceuticals Inc Product Sales [Member]", "terseLabel": "Scilex Pharmaceuticals Inc. Product Sales" } } }, "localname": "ScilexPharmaceuticalsIncProductSalesMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesScheduleOfRevenuesByCategoryDetails" ], "xbrltype": "domainItemType" }, "srne_SegregatedCollateralAccountFunding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Segregated Collateral Account Funding", "label": "Segregated Collateral Account Funding", "terseLabel": "Segregated collateral account funding" } } }, "localname": "SegregatedCollateralAccountFunding", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_SegregatedReserveAccountFunding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Segregated Reserve Account Funding", "label": "Segregated Reserve Account Funding", "terseLabel": "Segregated reserve account funding" } } }, "localname": "SegregatedReserveAccountFunding", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_SemnurCashExchangePaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Semnur cash exchange payment.", "label": "Semnur Cash Exchange Payment [Member]", "terseLabel": "Semnur Cash Exchange Payment" } } }, "localname": "SemnurCashExchangePaymentMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_SemnurPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Semnur Pharmaceuticals, Inc.", "label": "Semnur Pharmaceuticals Inc [Member]", "terseLabel": "Semnur" } } }, "localname": "SemnurPharmaceuticalsIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "srne_SeniorSecuredNotesDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Notes, Due 2026 [Member]", "label": "Senior Secured Notes Due2026 [Member]", "terseLabel": "Senior Secured Notes, Due 2026", "verboseLabel": "Scilex Notes" } } }, "localname": "SeniorSecuredNotesDue2026Member", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_ServiceCustomizedReagentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Service, Customized Reagents", "label": "Service Customized Reagents [Member]", "terseLabel": "Concortis Biosystems Corporation" } } }, "localname": "ServiceCustomizedReagentsMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesScheduleOfRevenuesByCategoryDetails" ], "xbrltype": "domainItemType" }, "srne_ServiceDrugAndReagantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Service, Drug and Reagants", "label": "Service Drug And Reagants [Member]", "terseLabel": "Bioserv Corporation" } } }, "localname": "ServiceDrugAndReagantsMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesScheduleOfRevenuesByCategoryDetails" ], "xbrltype": "domainItemType" }, "srne_ServiceJointDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Service, Joint Development", "label": "Service Joint Development [Member]", "terseLabel": "Joint development agreement" } } }, "localname": "ServiceJointDevelopmentMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesScheduleOfRevenuesByCategoryDetails" ], "xbrltype": "domainItemType" }, "srne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, released in period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period", "negatedLabel": "Number of Shares, RSUs Released" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfRestrictedStockUnitRsuActivityDetails" ], "xbrltype": "sharesItemType" }, "srne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, released, weighted average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value Per Share, RSUs Released" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfRestrictedStockUnitRsuActivityDetails" ], "xbrltype": "perShareItemType" }, "srne_ShareBasedCompensationEmployeeOptionGrantsVestingRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation employee option grants vesting rate.", "label": "Share Based Compensation Employee Option Grants Vesting Rate", "terseLabel": "Employee option grants vested" } } }, "localname": "ShareBasedCompensationEmployeeOptionGrantsVestingRate", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "srne_SharesTransferredForExchangeOfEquityInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares transferred for exchange of equity interest.", "label": "Shares Transferred For Exchange Of Equity Interest", "terseLabel": "Shares transferred for exchange of equity interest" } } }, "localname": "SharesTransferredForExchangeOfEquityInterest", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "srne_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Line Items]", "terseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srne_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Table]", "terseLabel": "Significant Accounting Policies [Table]" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srne_SignificantAgreementsAndContractsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant agreements and contracts.", "label": "Significant Agreements And Contracts [Abstract]" } } }, "localname": "SignificantAgreementsAndContractsAbstract", "nsuri": "http://sorrentotherapeutics.com/20211231", "xbrltype": "stringItemType" }, "srne_SignificantAgreementsAndContractsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant agreements and contracts.", "label": "Significant Agreements And Contracts [Text Block]", "terseLabel": "Significant Agreements and Contracts" } } }, "localname": "SignificantAgreementsAndContractsTextBlock", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContracts" ], "xbrltype": "textBlockItemType" }, "srne_SmartPharmMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SmartPharm.", "label": "Smart Pharm [Member]", "terseLabel": "SmartPharm Therapeutics, Inc." } } }, "localname": "SmartPharmMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_SmartPharmTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SmartPharm Therapeutics, Inc..", "label": "Smart Pharm Therapeutics Inc [Member]", "terseLabel": "SmartPharm" } } }, "localname": "SmartPharmTherapeuticsIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "srne_SorrentoStockIncentivePlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sorrento Stock Incentive Plans", "label": "Sorrento Stock Incentive Plans [Member]", "terseLabel": "Sorrento Stock Incentive Plans" } } }, "localname": "SorrentoStockIncentivePlansMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCommonStockReservedForFutureIssuanceAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_SorrentoTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sorrento Therapeutics [Member]", "label": "Sorrento Therapeutics [Member]", "terseLabel": "Sorrento Therapeutics" } } }, "localname": "SorrentoTherapeuticsMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfInformationByReportableSegmentsDetails" ], "xbrltype": "domainItemType" }, "srne_StockIssuedCommitmentFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued, Commitment Fee", "label": "Stock Issued Commitment Fee", "terseLabel": "Stock issued as commitment fee" } } }, "localname": "StockIssuedCommitmentFee", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAspireTransactionAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "srne_StockIssuedDuringPeriodSharesUponIssuanceOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares upon Issuance of warrants.", "label": "Stock Issued During Period Shares Upon Issuance Of Warrants", "terseLabel": "Issuance of common stock upon issuance of warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesUponIssuanceOfWarrants", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "srne_StockIssuedDuringPeriodValueUponIssuanceOfWarrant": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value upon issuance of warrant.", "label": "Stock Issued During Period Value Upon Issuance Of Warrant", "terseLabel": "Issuance of common stock upon exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodValueUponIssuanceOfWarrant", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "srne_StockIssuedDuringPeriodValueUponIssuanceOfWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value upon issuance of warrants.", "label": "Stock Issued During Period Value Upon Issuance Of Warrants", "terseLabel": "Issuance of common stock upon exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodValueUponIssuanceOfWarrants", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "srne_StockPurchasedAdditionalSharesValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock purchased additional shares value.", "label": "Stock Purchased Additional Shares Value", "terseLabel": "Stock purchased additional shares value" } } }, "localname": "StockPurchasedAdditionalSharesValue", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_StockPurchasedDuringPeriodSharesUnderEquityInvestments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock purchased during period shares under equity investments.", "label": "Stock Purchased During Period Shares Under Equity Investments", "terseLabel": "Shares purchased under equity investment" } } }, "localname": "StockPurchasedDuringPeriodSharesUnderEquityInvestments", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "srne_SuccessiveRenewalPeriods": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Successive renewal periods.", "label": "Successive Renewal Periods", "terseLabel": "Successive renewal periods" } } }, "localname": "SuccessiveRenewalPeriods", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "srne_TNKTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TNK Therapeutics Inc.", "label": "T N K Therapeutics Inc [Member]", "terseLabel": "TNK Therapeutics" } } }, "localname": "TNKTherapeuticsIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_TaxCreditCarryforwardsExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax credit carryforwards expiration year.", "label": "Tax Credit Carryforwards Expiration Year", "terseLabel": "Research and development credits expiration year" } } }, "localname": "TaxCreditCarryforwardsExpirationYear", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "srne_TechnologyPlacedInServiceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Technology placed in service.", "label": "Technology Placed In Service [Member]", "terseLabel": "Technology placed in service" } } }, "localname": "TechnologyPlacedInServiceMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srne_TermLoanTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan tranche one", "label": "Term Loan Tranche One [Member]", "terseLabel": "Oaktree Term Loan" } } }, "localname": "TermLoanTrancheOneMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails" ], "xbrltype": "domainItemType" }, "srne_TerminationWrittenNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination written notice period.", "label": "Termination Written Notice Period", "terseLabel": "Termination written notice" } } }, "localname": "TerminationWrittenNoticePeriod", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "srne_TrusteesOfColumbiaUniversityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trustees of Columbia University.", "label": "Trustees Of Columbia University [Member]", "terseLabel": "Columbia License Agreement" } } }, "localname": "TrusteesOfColumbiaUniversityMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithTheTrusteesOfColumbiaUniversityInCityOfNewYorkAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_TwoThousandNineteenStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen stock incentive plan.", "label": "Two Thousand Nineteen Stock Incentive Plan [Member]", "terseLabel": "2019 Stock Incentive Plan" } } }, "localname": "TwoThousandNineteenStockIncentivePlanMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCommonStockReservedForFutureIssuanceAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_TwoThousandNineteenStockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Nineteen Stock Option Plan [Member]", "label": "Two Thousand Nineteen Stock Option Plan [Member]", "terseLabel": "2019 Stock Option Plan" } } }, "localname": "TwoThousandNineteenStockOptionPlanMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansScilexHoldingCompanyAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_TwoThousandNineteenWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Nineteen Warrants [Member]", "label": "Two Thousand Nineteen Warrants [Member]", "terseLabel": "2019 Warrants" } } }, "localname": "TwoThousandNineteenWarrantsMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "srne_TwoThousandTwentyEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty employee stock purchase plan.", "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]", "terseLabel": "2020 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCommonStockReservedForFutureIssuanceAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansEmployeeStockPurchasePlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_UnrestrictedStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unrestricted stock.", "label": "Unrestricted Stock [Member]", "terseLabel": "Unrestricted Stock" } } }, "localname": "UnrestrictedStockMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_UpFrontLicenseFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Up-front license fee.", "label": "Up Front License Fee", "terseLabel": "Up-front license fee" } } }, "localname": "UpFrontLicenseFee", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAssetPurchaseAgreementWithAardvarkTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsLicenseAgreementWithIcahnSchoolOfMedicineAtMountSinaiAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithACEATherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithPersonalizedStemCellsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_UpFrontLicenseFeePayableWithinTenBusinessDays": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Up Front License Fee Payable Within Ten Business Days", "terseLabel": "Up-front license fee payable within ten business days" } } }, "localname": "UpFrontLicenseFeePayableWithinTenBusinessDays", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithTheTrusteesOfColumbiaUniversityInCityOfNewYorkAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_ValueOfSharesAvailableForIssuance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares available for issuance.", "label": "Value Of Shares Available For Issuance", "terseLabel": "Value of shares available for issuance" } } }, "localname": "ValueOfSharesAvailableForIssuance", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAspireTransactionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_VestedEquityReceivedUnderAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Vested equity received under agreement.", "label": "Vested Equity Received Under Agreement", "terseLabel": "Vested equity received" } } }, "localname": "VestedEquityReceivedUnderAgreement", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srne_VirexHealthIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Virex Health, Inc.", "label": "Virex Health, Inc [Member]", "terseLabel": "Virex Health, Inc" } } }, "localname": "VirexHealthIncMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_VirttuBiologicsLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Virttu Biologics Limited.", "label": "Virttu Biologics Limited [Member]", "terseLabel": "Virttu Biologics Limited" } } }, "localname": "VirttuBiologicsLimitedMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "srne_ZTlidoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ZTlido", "label": "Z Tlido [Member]", "terseLabel": "ZTlido" } } }, "localname": "ZTlidoMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srne_ZhejiangACEAPharmaceuticalCompanyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Zhejiang ACEA pharmaceutical company limited.", "label": "Zhejiang A C E A Pharmaceutical Company Limited [Member]", "terseLabel": "ACEA Zhejiang" } } }, "localname": "ZhejiangACEAPharmaceuticalCompanyLimitedMember", "nsuri": "http://sorrentotherapeutics.com/20211231", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r463", "r705", "r706", "r709", "r844" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r78", "r80", "r145", "r146", "r366", "r407" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r153", "r161", "r168", "r283", "r503", "r504", "r505", "r550", "r551", "r633", "r636", "r638", "r639", "r866" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r153", "r161", "r168", "r283", "r503", "r504", "r505", "r550", "r551", "r633", "r636", "r638", "r639", "r866" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r153", "r161", "r168", "r283", "r503", "r504", "r505", "r550", "r551", "r633", "r636", "r638", "r639", "r866" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantstemAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r249", "r445", "r449", "r819" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r365", "r406", "r466", "r469", "r725", "r726", "r727", "r728", "r729", "r730", "r749", "r817", "r820", "r845", "r846" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithACEATherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityEquityDistributionAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r365", "r406", "r466", "r469", "r725", "r726", "r727", "r728", "r729", "r730", "r749", "r817", "r820", "r845", "r846" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithACEATherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityEquityDistributionAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r249", "r445", "r449", "r819" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r246", "r445", "r447", "r752", "r816", "r818" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesScheduleOfRevenuesByCategoryDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r246", "r445", "r447", "r752", "r816", "r818" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesScheduleOfRevenuesByCategoryDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r365", "r406", "r455", "r466", "r469", "r725", "r726", "r727", "r728", "r729", "r730", "r749", "r817", "r820", "r845", "r846" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithACEATherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityEquityDistributionAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r365", "r406", "r455", "r466", "r469", "r725", "r726", "r727", "r728", "r729", "r730", "r749", "r817", "r820", "r845", "r846" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithACEATherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityEquityDistributionAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r79", "r80", "r145", "r146", "r366", "r407" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DocumentCover" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r162", "r467" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Scenario Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r162", "r168", "r467" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantstemAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r162", "r168", "r337", "r467", "r717" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r251", "r708" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r725", "r727", "r730", "r845", "r846" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201912Member": { "auth_ref": [ "r548", "r549", "r550", "r551" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.", "label": "Accounting Standards Update 2019-12 [Member]", "terseLabel": "ASU 2019-12" } } }, "localname": "AccountingStandardsUpdate201912Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r155", "r156", "r157", "r158", "r259", "r260", "r280", "r281", "r282", "r283", "r285", "r286", "r348", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r550", "r551", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r658", "r659", "r661", "r662", "r663", "r664", "r665", "r666", "r702", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r864", "r865", "r866", "r867", "r868" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r52", "r714" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r10", "r39", "r252", "r253" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivables, net", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Accrued Liabilities, Current, Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r50", "r324" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r42", "r83", "r84", "r85", "r799", "r828", "r832" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r82", "r85", "r93", "r94", "r95", "r150", "r151", "r152", "r609", "r823", "r824", "r868" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r40" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r150", "r151", "r152", "r503", "r504", "r505", "r638" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r123", "r315" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "terseLabel": "Intangible amortization", "totalLabel": "Amortization, Total" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r155", "r156", "r157", "r158", "r168", "r259", "r260", "r280", "r281", "r282", "r283", "r285", "r286", "r348", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r548", "r549", "r550", "r551", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r658", "r659", "r661", "r662", "r663", "r664", "r665", "r666", "r702", "r754", "r755", "r756", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r864", "r865", "r866", "r867", "r868" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r420", "r427", "r547" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature", "terseLabel": "Beneficial conversion feature recorded on convertible notes" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r361", "r420", "r427" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Warrants issued in connection with convertible notes", "verboseLabel": "Loss on debt extinguishment" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used for operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r471", "r495", "r508" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansEmployeeStockPurchasePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansScilexHoldingCompanyAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AlternativeInvestmentMeasurementInput": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure alternative investment.", "label": "Alternative Investment, Measurement Input", "terseLabel": "Discount rate for lack of marketability" } } }, "localname": "AlternativeInvestmentMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r123", "r385", "r395", "r396", "r682" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amount of debt discount and debt issuance included in interest expense", "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of Earnings Per Share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareOutstandingSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareOutstandingSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareOutstandingSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareOutstandingSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Rentable area" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAssetPurchaseAgreementWithAardvarkTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSmartpharmTherapeuticsIncAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r591", "r592", "r593", "r594" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Consideration transferred", "totalLabel": "Asset Acquisition, Consideration Transferred, Total" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSmartpharmTherapeuticsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAssetPurchaseAgreementWithAardvarkTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSmartpharmTherapeuticsIncAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r139", "r228", "r235", "r242", "r274", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r602", "r610", "r657", "r712", "r714", "r773", "r795" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r13", "r15", "r76", "r139", "r274", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r602", "r610", "r657", "r712", "r714" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "terseLabel": "Current assets of equity method investment", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantstemAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r641" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r21", "r22", "r23", "r24", "r25", "r26", "r27", "r28", "r139", "r274", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r602", "r610", "r657", "r712" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "terseLabel": "Noncurrent assets of equity method investment", "totalLabel": "Assets, Noncurrent, Total" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantstemAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r472", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCommonStockReservedForFutureIssuanceAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansFairValueOfEmployeeAndDirectorStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Principles of Consolidation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BridgeLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place.", "label": "Bridge Loan [Member]", "terseLabel": "Bridge Loan" } } }, "localname": "BridgeLoanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsShortTermLoansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r465", "r468" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentConsiderationLiabilitiesAreMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3De", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsLicenseAgreementWithIcahnSchoolOfMedicineAtMountSinaiAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r465", "r468", "r571", "r572" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentConsiderationLiabilitiesAreMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3De", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsLicenseAgreementWithIcahnSchoolOfMedicineAtMountSinaiAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when the business acquisition agreement was executed, in YYYY-MM-DD format.", "label": "Business Acquisition, Date of Acquisition Agreement", "terseLabel": "Business acquisition, date of acquisition agreement" } } }, "localname": "BusinessAcquisitionDateOfAcquisitionAgreement1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": { "auth_ref": [ "r566", "r567", "r569" ], "lang": { "en-us": { "role": { "documentation": "Date when the acquirer obtains control of the acquiree, in YYYY-MM-DD format.", "label": "Business Acquisition, Effective Date of Acquisition", "terseLabel": "Business acquisition, effective date of acquisition" } } }, "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r586" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Stock consideration shares" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsLicenseAgreementWithIcahnSchoolOfMedicineAtMountSinaiAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionNameOfAcquiredEntity": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "Name of the acquired entity.", "label": "Business Acquisition, Name of Acquired Entity", "terseLabel": "Business acquisition, name of acquired entity" } } }, "localname": "BusinessAcquisitionNameOfAcquiredEntity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Business acquisition, percentage of voting interests acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Share price" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r565" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Business combination acquisition related cost" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r580", "r581", "r584" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total purchase consideration", "totalLabel": "Business Combination, Consideration Transferred, Total" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r580", "r581" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Stock consideration common stock value", "verboseLabel": "Stock consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r122", "r589" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Acquisition consideration payable", "verboseLabel": "(Gain) related to the settlement of acquisition consideration payable" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r588" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Contingent consideration payable", "verboseLabel": "Business combination additional payments" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r579", "r582", "r587" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration, liability", "totalLabel": "Business Combination, Contingent Consideration, Liability, Total" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r579", "r583" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Acquisition consideration payable", "verboseLabel": "Current portion of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r579", "r583" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized": { "auth_ref": [ "r575" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity.", "label": "Business Combination, Liabilities Arising from Contingencies, Amount Recognized", "terseLabel": "Fair value of earn out consideration" } } }, "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r574" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "terseLabel": "Purchase price allocation resulted in net identifiable assets", "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSmartpharmTherapeuticsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": { "auth_ref": [ "r573", "r574" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r574" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "terseLabel": "Deferred tax liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r574" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "Purchase price allocation resulted in net identifiable assets, indefinite lived intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSmartpharmTherapeuticsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r574" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Purchase price allocation resulted in net identifiable assets, intangible assets", "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r574" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt", "terseLabel": "Fair value of debt assumed liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r574" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Purchase price allocation resulted in net identifiable assets, other net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSmartpharmTherapeuticsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Acquisitions, Contingent Consideration and Acquired In-Process Research and Development" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r128", "r129", "r130" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment costs incurred but not paid" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r46", "r125" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "verboseLabel": "Unrestricted cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfInformationByReportableSegmentsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r20", "r126" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r118", "r125", "r131" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance", "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance", "totalLabel": "Cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash within the Company's consolidated balance sheets:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r118", "r125", "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r118", "r671" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net change in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r0", "r1", "r150", "r151", "r154", "r259", "r260", "r276", "r277", "r278", "r280", "r281", "r348", "r499", "r500", "r501", "r548", "r625", "r630", "r631", "r658", "r660", "r661", "r662", "r665", "r666", "r686", "r702", "r754", "r755", "r821", "r822", "r864" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r0", "r1", "r150", "r151", "r161", "r259", "r260", "r276", "r277", "r278", "r280", "r281", "r348", "r499", "r500", "r501", "r548", "r625", "r630", "r631", "r632", "r635", "r658", "r660", "r661", "r662", "r665", "r666", "r686", "r702", "r754", "r755", "r821", "r822", "r864" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.", "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": { "auth_ref": [ "r4", "r154", "r260", "r276", "r279", "r282", "r348", "r502", "r549", "r625", "r632", "r635", "r659", "r660", "r663", "r664", "r666", "r686", "r756", "r821", "r822", "r840" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was early adopted.", "label": "Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "auth_ref": [ "r155", "r167", "r261", "r284", "r506", "r552" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.", "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r136", "r139", "r171", "r174", "r186", "r190", "r193", "r205", "r206", "r207", "r274", "r349", "r353", "r354", "r355", "r358", "r359", "r404", "r405", "r409", "r413", "r657", "r855" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity2019PublicOfferingOfCommonStockAndWarrantsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAspireTransactionAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockPurchaseAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityEquityDistributionAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r431", "r470" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrant exercise price per share (USD per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of common stock shares called by warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollateralAxis": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Information by category of collateral or no collateral, from lender's perspective.", "label": "Collateral Held [Axis]", "terseLabel": "Collateral Held" } } }, "localname": "CollateralAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsShortTermLoansAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollateralDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of collateral or no collateral, from lender's perspective.", "label": "Collateral Held [Domain]", "terseLabel": "Collateral Held" } } }, "localname": "CollateralDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsShortTermLoansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollateralPledgedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pledge of specific property to serve as protection against default.", "label": "Collateral Pledged [Member]", "terseLabel": "Collateral Pledged" } } }, "localname": "CollateralPledgedMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsShortTermLoansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r64", "r336", "r779", "r804" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r333", "r334", "r335", "r340", "r839" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Class A Common Stock" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCommonStockReservedForFutureIssuanceAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansScilexHoldingCompanyAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r150", "r151", "r638" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (USD per share)", "verboseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r38", "r420" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r38", "r714" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.0001 par value; 750,000,000 shares authorized and 314,573,225 and 275,285,582 shares issued and outstanding at December 31, 2021 and 2020, respectively", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensatingBalanceAmount": { "auth_ref": [ "r46" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability.", "label": "Compensating Balance, Amount", "terseLabel": "Compensating balance" } } }, "localname": "CompensatingBalanceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r88", "r90", "r91", "r102", "r785", "r810" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss attributable to Sorrento" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r88", "r90", "r101", "r599", "r600", "r614", "r784", "r809" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive loss attributable to noncontrolling interests", "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r88", "r90", "r100", "r598", "r614", "r783", "r808" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r433", "r434", "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "totalLabel": "Contract with Customer, Liability, Total", "verboseLabel": "Upfront payment received from customers" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r433", "r434", "r446" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Current portion of deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r433", "r434", "r446" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r360", "r362", "r363", "r365", "r375", "r376", "r377", "r381", "r382", "r383", "r384", "r385", "r393", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r105", "r139", "r274", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r657" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of product sold and services", "totalLabel": "Cost of Revenue, Total" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r104" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "terseLabel": "Operating expenses", "totalLabel": "Total operating costs and expenses", "verboseLabel": "Operating costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureQuarterlyFinancialDataUnauditedScheduleOfQuarterlyFinancialDataDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfInformationByReportableSegmentsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r140", "r542", "r555" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails": { "order": 0.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r140", "r542" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r140", "r542", "r555", "r557" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current income tax expense (benefit):" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r140", "r542", "r555" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r135", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r379", "r386", "r387", "r389", "r399" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r30", "r31", "r32", "r138", "r148", "r362", "r363", "r364", "r365", "r366", "r367", "r369", "r375", "r376", "r377", "r378", "r380", "r381", "r382", "r383", "r384", "r385", "r393", "r394", "r395", "r396", "r684", "r774", "r776", "r794" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCollateralAmount": { "auth_ref": [ "r790" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets pledged to secure a debt instrument.", "label": "Debt Instrument, Collateral Amount", "terseLabel": "Collateral amount" } } }, "localname": "DebtInstrumentCollateralAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsShortTermLoansAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r362", "r393", "r394", "r681", "r684", "r685" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Principal", "terseLabel": "Face value of loan", "verboseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r377", "r393", "r394", "r656" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Estimated fair value", "totalLabel": "Debt Instrument, Fair Value Disclosure, Total" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r138" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt Instrument, Increase, Accrued Interest", "terseLabel": "Unpaid accrued interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r60", "r391", "r681", "r684" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt instrument, interest rate, effective percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r60", "r363" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r61", "r365", "r646" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Maturity Date", "verboseLabel": "Debt instrument maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateRangeEnd1": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date Range, End", "terseLabel": "Debt instrument, maturity date range, end" } } }, "localname": "DebtInstrumentMaturityDateRangeEnd1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateRangeStart1": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date Range, Start", "terseLabel": "Debt instrument, maturity date range, start" } } }, "localname": "DebtInstrumentMaturityDateRangeStart1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r62", "r138", "r148", "r362", "r363", "r364", "r365", "r366", "r367", "r369", "r375", "r376", "r377", "r378", "r380", "r381", "r382", "r383", "r384", "r385", "r393", "r394", "r395", "r396", "r684" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Principal payments" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r791" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r791" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r791" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "Prior to August 15, 2026" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r791" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price as a percentage of outstanding principal" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r62", "r138", "r148", "r362", "r363", "r364", "r365", "r366", "r367", "r369", "r375", "r376", "r377", "r378", "r380", "r381", "r382", "r383", "r384", "r385", "r388", "r393", "r394", "r395", "r396", "r421", "r424", "r425", "r426", "r680", "r681", "r684", "r685", "r792" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtAceaSignificantDebtArrangementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r375", "r680", "r685" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Unamortized debt discount", "terseLabel": "Debt discount", "totalLabel": "Debt Instrument, Unamortized Discount, Total" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r375", "r680", "r681", "r682", "r683", "r685" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "negatedLabel": "Unamortized capitalized debt issuance costs", "totalLabel": "Debt Instrument, Unamortized Discount (Premium), Net, Total" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt, Policy [Policy Text Block]", "terseLabel": "Debt, Including Debt With Detachable Warrants" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r140", "r543", "r555" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r51", "r375", "r682" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt issuance costs", "totalLabel": "Debt Issuance Costs, Net, Total" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r140", "r543", "r555" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r123", "r140", "r543", "r555", "r556", "r557" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes", "totalLabel": "Total deferred" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred income tax expense (benefit):" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r34", "r35", "r532", "r775", "r793" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities", "totalLabel": "Deferred Tax Liabilities, Gross, Total" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r518", "r519" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities, net", "totalLabel": "Deferred Income Tax Liabilities, Net, Total" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r124" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes", "totalLabel": "Deferred Income Taxes and Tax Credits, Total" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r140", "r543", "r555" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r540", "r541" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets, Deferred Income", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r533" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r535" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r538", "r540", "r541" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit carryforwards", "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r540", "r541" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Stock based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": { "auth_ref": [ "r540", "r541" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Other", "terseLabel": "Accrued expenses and other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r534" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less valuation allowance", "terseLabel": "Valuation allowance", "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r519", "r535" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred tax liabilities", "totalLabel": "Deferred Tax Liabilities, Net, Total" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r540", "r541" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "negatedLabel": "Intangible assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesInvestments": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).", "label": "Deferred Tax Liabilities, Investments", "negatedLabel": "Investment in common stock" } } }, "localname": "DeferredTaxLiabilitiesInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r540", "r541" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfNetDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Employer matching contributions" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansEmployeeBenefitPlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r123", "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense", "totalLabel": "Depreciation, Total" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r123", "r322" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.", "label": "Derivative Financial Instruments, Liabilities [Member]", "terseLabel": "Derivative Liabilities" } } }, "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r620" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "negatedLabel": "Loss (gain) loss on derivative liability", "terseLabel": "(Loss) gain on derivative liabilities", "totalLabel": "Derivative, Gain (Loss) on Derivative, Net, Total" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r80", "r619", "r621", "r622", "r623" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r77" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "terseLabel": "Derivative liabilities" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative Liability, Measurement Input", "terseLabel": "Derivative liability, measurement input" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativeLossOnDerivative": { "auth_ref": [ "r620" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Loss on Derivative", "terseLabel": "Loss on derivative liability", "verboseLabel": "Loss on derivative liabilities" } } }, "localname": "DerivativeLossOnDerivative", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r147", "r615", "r616", "r617", "r618", "r624" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Liabilities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Acquired technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesScheduleOfRevenuesByCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r445", "r447", "r448", "r449", "r450", "r451", "r452", "r453" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesScheduleOfRevenuesByCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r103", "r159", "r160", "r161", "r162", "r163", "r169", "r171", "r190", "r192", "r193", "r197", "r198", "r639", "r640", "r786", "r811" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic loss per share", "terseLabel": "Net loss per share - basic per share attributable to Sorrento", "totalLabel": "Earnings Per Share, Basic, Total", "verboseLabel": "Net loss per share - basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareReconciliationOfBasicAndDilutedEarningsPerShareDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureQuarterlyFinancialDataUnauditedScheduleOfQuarterlyFinancialDataDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r103", "r159", "r160", "r161", "r162", "r163", "r171", "r190", "r192", "r193", "r197", "r198", "r639", "r640", "r786", "r811" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted loss per share", "terseLabel": "Net loss per share - diluted per share attributable to Sorrento", "totalLabel": "Earnings Per Share, Diluted, Total", "verboseLabel": "Net loss per share - diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareReconciliationOfBasicAndDilutedEarningsPerShareDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureQuarterlyFinancialDataUnauditedScheduleOfQuarterlyFinancialDataDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r194", "r195" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r194", "r195", "r196", "r199" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r671" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Net effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and related benefits", "totalLabel": "Employee-related Liabilities, Current, Total" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Period for recognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansScilexHoldingCompanyAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r496" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost related to unvested stock option grants" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansScilexHoldingCompanyAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Employee Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareOutstandingSecuritiesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCommonStockReservedForFutureIssuanceAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansFairValueOfEmployeeAndDirectorStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r93", "r94", "r95", "r150", "r151", "r152", "r156", "r164", "r166", "r204", "r283", "r420", "r427", "r503", "r504", "r505", "r550", "r551", "r638", "r672", "r673", "r674", "r675", "r676", "r677", "r823", "r824", "r825", "r868" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCommonStockReservedForFutureIssuanceAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": { "auth_ref": [ "r269" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.", "label": "Equity Method Investment, Other than Temporary Impairment", "terseLabel": "Loss on equity investments" } } }, "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantstemAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity method investment ownership percentage", "verboseLabel": "Equity interest" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r47", "r229", "r270" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity investments", "verboseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantstemAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "auth_ref": [ "r654" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.", "label": "Equity Securities, FV-NI, Noncurrent", "terseLabel": "Equity investments" } } }, "localname": "EquitySecuritiesFVNINoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r654" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Cost-method investments, aggregate carrying amount" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r268" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "terseLabel": "Equity method investment, impairment losses", "totalLabel": "Equity Securities, FV-NI, Gain (Loss), Total" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r268", "r813" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "terseLabel": "Unrealized gain (loss) on equity investment", "totalLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss), Total" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r265" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity security without readily determinable fair value, amount" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r641", "r642", "r643", "r651" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r647" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r647", "r651" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r641", "r651" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r377", "r393", "r394", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r464", "r642", "r722", "r723", "r724" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r650", "r651" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r641", "r642", "r645", "r646", "r652" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r650" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r377", "r456", "r457", "r462", "r464", "r642", "r722" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r377", "r393", "r394", "r456", "r457", "r462", "r464", "r642", "r723" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r377", "r393", "r394", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r464", "r642", "r724" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r647" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentConsiderationLiabilitiesAreMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3De" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r647", "r651" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentConsiderationLiabilitiesAreMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3De" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r647", "r651" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r648" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedLabel": "Re-measurement of Fair Value", "terseLabel": "Re-measurement of Fair Value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentConsiderationLiabilitiesAreMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3De", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "auth_ref": [ "r649" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "terseLabel": "Additions", "verboseLabel": "Contingent consideration related to the acquisition of ACEA Therapeutics, Inc." } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentConsiderationLiabilitiesAreMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3De", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r649" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedLabel": "Settlements of contingent consideration", "terseLabel": "Settlement of contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentConsiderationLiabilitiesAreMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3De", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r647" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentConsiderationLiabilitiesAreMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3De", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r377", "r393", "r394", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r464", "r722", "r723", "r724" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r650", "r652" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r653", "r655" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r263", "r264", "r265", "r266", "r267", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r295", "r296", "r388", "r418", "r628", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r855", "r856", "r857", "r858", "r859", "r860", "r861" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialStandbyLetterOfCreditMember": { "auth_ref": [ "r341", "r345" ], "lang": { "en-us": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation if defined events occur or fail to occur.", "label": "Financial Standby Letter of Credit [Member]", "terseLabel": "Standby Letters of Credit" } } }, "localname": "FinancialStandbyLetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Weighted Average Amortization Period (Years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r314" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r316" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetails": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r316" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r316" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r316" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r316" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r309", "r311", "r314", "r318", "r753", "r757" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r314", "r757" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails": { "order": 0.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount", "totalLabel": "Finite-Lived Intangible Assets, Gross, Total" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r309", "r313" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r314", "r753" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance", "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r753" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Identifiable intangible assets, weighted average life" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r667", "r668", "r669", "r670" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "(Loss) gain on foreign currency exchange", "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r619" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Loss on derivative liability", "totalLabel": "Gain (Loss) on Derivative Instruments, Net, Pretax, Total" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r107", "r123", "r262" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "negatedLabel": "Loss on marketable investments", "totalLabel": "Gain (Loss) on Investments, Total" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r123", "r397", "r398" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on debt extinguishment, net", "negatedTerseLabel": "Loss on debt extinguishment", "terseLabel": "Loss on debt extinguishment", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r106" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "Selling, general and administrative", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r302", "r304", "r714", "r772" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, Ending Balance", "periodStartLabel": "Goodwill, Beginning Balance", "terseLabel": "Goodwill", "totalLabel": "Goodwill, Total" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSmartpharmTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r123", "r303", "r305", "r307" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Goodwill, period increase (decrease)", "totalLabel": "Goodwill, Period Increase (Decrease), Total" } } }, "localname": "GoodwillPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteeObligationsByNatureAxis": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Information by nature of guarantee.", "label": "Guarantor Obligations, Nature [Axis]", "terseLabel": "Guarantor Obligations, Nature" } } }, "localname": "GuaranteeObligationsByNatureAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GuaranteeObligationsMaximumExposure": { "auth_ref": [ "r343" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.", "label": "Guarantor Obligations, Maximum Exposure, Undiscounted", "terseLabel": "Maximum exposure under guarantor obligations" } } }, "localname": "GuaranteeObligationsMaximumExposure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteeObligationsNatureDomain": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees.", "label": "Guarantor Obligations, Nature [Domain]", "terseLabel": "Guarantor Obligations, Nature" } } }, "localname": "GuaranteeObligationsNatureDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r123", "r319" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Loss on IPR&D impairment" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r123", "r321", "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Impairment losses of long-lived assets", "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Other Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "Acquired in-process research and development", "verboseLabel": "Acquired in-process research and development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r141", "r558" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxByLocationDetails": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "United States" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxByLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r97", "r228", "r234", "r238", "r241", "r244", "r770", "r781", "r788", "r814" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxByLocationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before income tax", "totalLabel": "Loss before income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxByLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r141", "r558" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxByLocationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxByLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r228", "r234", "r238", "r241", "r244" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r98", "r123", "r225", "r270", "r780", "r806" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "Loss on equity method investments", "terseLabel": "Loss on equity method investments", "totalLabel": "Income (Loss) from Equity Method Investments, Total" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r327", "r330" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r142", "r522", "r530", "r537", "r553", "r559", "r561", "r562", "r563" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationInterestExpense": { "auth_ref": [ "r523" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated interest recognized in the period arising from income tax examinations.", "label": "Income Tax Examination, Interest Expense", "terseLabel": "Interest recognized" } } }, "localname": "IncomeTaxExaminationInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r143", "r165", "r166", "r226", "r520", "r554", "r560", "r815" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax benefit", "totalLabel": "Total income tax benefit from continuing operations" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": { "auth_ref": [ "r544" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.", "label": "Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability", "terseLabel": "Changes in tax rate" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r92", "r516", "r517", "r530", "r531", "r536", "r545" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r521" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Valuation allowance", "verboseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r521" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Income tax benefit at federal statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r521" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount", "terseLabel": "Compensation expense" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r521" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r521" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount", "terseLabel": "Prior year true-up and carryback" } } }, "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r521" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State, net of federal tax benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationBetweenFederalIncomeTaxAndCompanyProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r127" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes", "totalLabel": "Income Taxes Paid, Net, Total" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r122" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r122" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r122", "r750" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r122" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r122" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued payroll", "totalLabel": "Increase (Decrease) in Employee Related Liabilities, Total" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities, excluding effect of acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r122" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r122" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Accounts receivable", "totalLabel": "Increase (Decrease) in Receivables, Total" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares": { "auth_ref": [ "r172", "r173", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r193" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareReconciliationOfBasicAndDilutedEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares", "terseLabel": "Potentially dilutive shares of Sorrento common stock issuable upon Semnur Share Exchange" } } }, "localname": "IncrementalCommonSharesAttributableToContingentlyIssuableShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareReconciliationOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r317" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "periodEndLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance", "periodStartLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Beginning Balance", "terseLabel": "Indefinite-lived intangible assets", "totalLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Total" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r308", "r312" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangibles, net", "totalLabel": "Intangibles, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r96", "r222", "r679", "r682", "r787" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense, net", "terseLabel": "Interest expense, net", "totalLabel": "Interest Expense, Total" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r109", "r383", "r392", "r395", "r396" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest expense", "totalLabel": "Interest Expense, Debt, Total" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r116", "r120", "r127" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "IRS" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods", "totalLabel": "Inventory, Finished Goods, Gross, Total" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r9", "r73", "r714" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Inventory, Net, Total", "verboseLabel": "Net inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r16", "r74", "r133", "r200", "r297", "r298", "r299", "r751" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Raw materials and supplies", "totalLabel": "Inventory, Raw Materials and Supplies, Gross, Total" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r272", "r812" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments in Other Entities" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets held for their financial return, rather than for the entity's operations.", "label": "Investments [Member]", "terseLabel": "Marketable investments" } } }, "localname": "InvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseAgreementsMember": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.", "label": "Lease Agreements [Member]", "terseLabel": "Lease Agreement" } } }, "localname": "LeaseAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r699" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Supplemental Quantitative Information Related to Leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r691" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r700" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Operating Lease Liability Maturities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r700" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Total lease future payments", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r700" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r700" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r700" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r700" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r700" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r700" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r700" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r692" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Operating lease remaining lease terms" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r693" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating lease option to extend, period" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r693" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease, term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r56", "r139", "r236", "r274", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r603", "r610", "r611", "r657", "r712", "r713" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r45", "r139", "r274", "r657", "r714", "r778", "r802" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r59", "r139", "r274", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r603", "r610", "r611", "r657", "r712", "r713", "r714" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "terseLabel": "Current liabilities of equity method investment", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantstemAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r641" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r17", "r18", "r19", "r32", "r33", "r139", "r274", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r603", "r610", "r611", "r657", "r712", "r713" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "terseLabel": "Noncurrent liabilities of equity method investment", "totalLabel": "Liabilities, Noncurrent, Total" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantstemAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r32", "r776", "r794" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Outstanding balance", "totalLabel": "Long-term Line of Credit, Total" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r53", "r138" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r53", "r138" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r32", "r376", "r390", "r393", "r394", "r776", "r797" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtFutureMinimumPaymentsDetails2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Carrying value", "verboseLabel": "Carrying value" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r55" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtFutureMinimumPaymentsDetails2": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedLabel": "Current portion", "terseLabel": "Current portion of debt", "totalLabel": "Long-term Debt, Current Maturities, Total" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r148", "r346", "r381" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails": { "order": 5.0, "parentTag": "srne_LongTermDebtMaturitiesRepaymentsOfPrincipalAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r148", "r346", "r381" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails": { "order": 0.0, "parentTag": "srne_LongTermDebtMaturitiesRepaymentsOfPrincipalAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r148", "r346", "r381" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails": { "order": 4.0, "parentTag": "srne_LongTermDebtMaturitiesRepaymentsOfPrincipalAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r148", "r346", "r381" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails": { "order": 3.0, "parentTag": "srne_LongTermDebtMaturitiesRepaymentsOfPrincipalAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r148", "r346", "r381" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails": { "order": 2.0, "parentTag": "srne_LongTermDebtMaturitiesRepaymentsOfPrincipalAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r148", "r346", "r381" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails": { "order": 1.0, "parentTag": "srne_LongTermDebtMaturitiesRepaymentsOfPrincipalAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r62" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebtFutureMinimumPaymentsDetails2": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net of discount", "totalLabel": "Long-term Debt, Excluding Current Maturities, Total", "verboseLabel": "Long-term portion of Scilex Notes" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r62", "r347" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r336", "r338", "r339" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Damages sought" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and lab equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r11", "r57" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable investments", "totalLabel": "Marketable Securities, Current, Total", "verboseLabel": "Common stock shares value subject to transfer restrictions" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesGainLoss": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Gain (Loss)", "terseLabel": "Loss on marketable investments", "totalLabel": "Marketable Securities, Gain (Loss), Total" } } }, "localname": "MarketableSecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesRealizedGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Realized Gain (Loss)", "terseLabel": "Realized gain (loss) on marketable investments", "totalLabel": "Marketable Securities, Realized Gain (Loss), Total" } } }, "localname": "MarketableSecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputCreditSpreadMember": { "auth_ref": [ "r644" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using amount above (below) yield between two debt instruments similar in maturity, but different in credit quality.", "label": "Measurement Input, Credit Spread [Member]", "terseLabel": "Effective Debt Yield" } } }, "localname": "MeasurementInputCreditSpreadMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": { "auth_ref": [ "r644" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly.", "label": "Measurement Input, Discount for Lack of Marketability [Member]", "terseLabel": "Discount for lack of marketability" } } }, "localname": "MeasurementInputDiscountForLackOfMarketabilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputLongTermRevenueGrowthRateMember": { "auth_ref": [ "r644" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using compounded annualized rate of long-term growth in revenue.", "label": "Measurement Input, Long-term Revenue Growth Rate [Member]", "terseLabel": "Risk Adjusted Net Sales Forecast" } } }, "localname": "MeasurementInputLongTermRevenueGrowthRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRevenueMultipleMember": { "auth_ref": [ "r644" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using market valuation of entity divided by revenue.", "label": "Measurement Input, Revenue Multiple [Member]", "terseLabel": "Revenue Multiple" } } }, "localname": "MeasurementInputRevenueMultipleMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r644" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r70", "r139", "r274", "r349", "r353", "r354", "r355", "r358", "r359", "r657", "r777", "r801" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "periodEndLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance", "periodStartLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance", "terseLabel": "Noncontrolling interests", "totalLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Total" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Noncontrolling interest ownership percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r118" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r118" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used for investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r118", "r121", "r124" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used for operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r6", "r86", "r89", "r95", "r99", "r124", "r139", "r155", "r159", "r160", "r161", "r162", "r165", "r166", "r187", "r228", "r234", "r238", "r241", "r244", "r274", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r640", "r657", "r782", "r807" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareReconciliationOfBasicAndDilutedEarningsPerShareDetails": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss (income) attributable to Sorrento", "totalLabel": "Net loss attributable to Sorrento" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareReconciliationOfBasicAndDilutedEarningsPerShareDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureQuarterlyFinancialDataUnauditedScheduleOfQuarterlyFinancialDataDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r86", "r89", "r95", "r165", "r166", "r605", "r613" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net loss attributable to noncontrolling interests", "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r170", "r175", "r176", "r177", "r178", "r189", "r193" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareReconciliationOfBasicAndDilutedEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net loss used for diluted earnings per share" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareReconciliationOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "auth_ref": [ "r428", "r601", "r607" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "terseLabel": "Adjustment to noncontrolling interest" } } }, "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r150", "r151", "r152", "r427", "r596" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingGainsLosses": { "auth_ref": [ "r108" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth).", "label": "Nonoperating Gains (Losses)", "terseLabel": "Other income gain (loss)", "totalLabel": "Nonoperating Gains (Losses), Total" } } }, "localname": "NonoperatingGainsLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableRelatedParties": { "auth_ref": [ "r144", "r706", "r805" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.", "label": "Notes Receivable, Related Parties", "terseLabel": "Aggregate loan amount" } } }, "localname": "NotesReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Costs and Expenses [Abstract]", "terseLabel": "Operating costs and expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r228", "r234", "r238", "r241", "r244" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating (loss) income", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfInformationByReportableSegmentsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r689" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r688" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Operating Lease, Liability, Total", "verboseLabel": "Total lease liabilities as of December 31, 2021" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r688" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r688" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r690", "r695" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash outflows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSupplementalQuantitativeInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r687" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r698", "r701" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSupplementalQuantitativeInformationRelatedToLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r697", "r701" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term in years" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSupplementalQuantitativeInformationRelatedToLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r538" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforward", "totalLabel": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "auth_ref": [ "r400", "r626", "r627", "r629" ], "lang": { "en-us": { "role": { "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.", "label": "Option Indexed to Issuer's Equity, Type [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed to Issuer's Equity, Type [Domain]" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r75", "r714" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r51" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets, net", "totalLabel": "Other Assets, Noncurrent, Total" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r81" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total", "verboseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r87", "r90", "r598", "r599", "r608" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r63" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "totalLabel": "Other Liabilities, Noncurrent, Total" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r123" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Paid-in-Kind Interest", "terseLabel": "Non-cash interest expense and amortization of debt issuance costs" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patent rights" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "auth_ref": [ "r115" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "terseLabel": "Debt prepayment costs" } } }, "localname": "PaymentsOfDebtExtinguishmentCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r110", "r585" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration to equity holders", "verboseLabel": "Payments to acquire businesses gross" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r110" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisition consideration paid in cash, net of cash acquired", "totalLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r111" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r472", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCommonStockReservedForFutureIssuanceAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansEmployeeStockPurchasePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansScilexHoldingCompanyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCommonStockReservedForFutureIssuanceAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansEmployeeStockPurchasePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansScilexHoldingCompanyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r12", "r14", "r300", "r301" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses", "totalLabel": "Prepaid Expense, Current, Total" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]", "terseLabel": "Prime Rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r113" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from issuance of convertible notes" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCustomers": { "auth_ref": [ "r119" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services.", "label": "Proceeds from Customers", "terseLabel": "Proceeds from customers" } } }, "localname": "ProceedsFromCustomers", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r112" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Proceeds from equity offerings, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityEquityDistributionAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r113" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from Oaktree Term Loans, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "auth_ref": [ "r113" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).", "label": "Proceeds from Issuance of Senior Long-term Debt", "terseLabel": "Proceeds from issuance of Scilex notes, net of issuance costs", "verboseLabel": "Proceeds from issuance of senior long-term debt" } } }, "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sale of marketable investments", "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromShortTermDebt": { "auth_ref": [ "r113" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from Short-term Debt", "terseLabel": "Proceeds from short-term debt and working capital funding arrangements, net of issuance costs", "totalLabel": "Proceeds from Short-term Debt, Total", "verboseLabel": "Short-term working capital funding arrangements, net of issuance costs" } } }, "localname": "ProceedsFromShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsShortTermLoansAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r112", "r498" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercises of stock options and warrants" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesScheduleOfRevenuesByCategoryDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r6", "r86", "r89", "r95", "r117", "r139", "r155", "r165", "r166", "r228", "r234", "r238", "r241", "r244", "r274", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r598", "r604", "r606", "r613", "r614", "r640", "r657", "r788" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net Income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantstemAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r50", "r325" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r329", "r841", "r842", "r843" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r49", "r323" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Property and equipment", "totalLabel": "Property, Plant and Equipment, Gross, Total", "verboseLabel": "Property and equipment, total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r24", "r25", "r325", "r714", "r789", "r803" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r48", "r325", "r841", "r842" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r24", "r325" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r24", "r323" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life of fixed asset" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PutOptionMember": { "auth_ref": [ "r833", "r834", "r835", "r836", "r837", "r838" ], "lang": { "en-us": { "role": { "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option.", "label": "Put Option [Member]", "terseLabel": "Put Option" } } }, "localname": "PutOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r202", "r203" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Quarterly Financial Data (Unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureQuarterlyFinancialDataUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r254", "r256", "r257", "r258" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable, Net" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxExpenseBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r463", "r705", "r706" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r463", "r705", "r706", "r709" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Purchases from Related Party", "terseLabel": "Purchases from related party" } } }, "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r463", "r705", "r709", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r703", "r704", "r706", "r710", "r711" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Agreements and Other" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOther" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r114" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Repayments of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018OaktreeTermLoanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r114" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Payments of debt and other obligations", "totalLabel": "Repayments of Long-term Debt, Total" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r114" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-term Debt", "terseLabel": "Repayments of arrangements", "totalLabel": "Repayments of Short-term Debt, Total" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsShortTermLoansAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAssetPurchaseAgreementWithAardvarkTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsLicenseAgreementWithIcahnSchoolOfMedicineAtMountSinaiAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSmartpharmTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithACEATherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithPersonalizedStemCellsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithTheTrusteesOfColumbiaUniversityInCityOfNewYorkAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsShortTermLoansAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off", "terseLabel": "Acquired in-process research and development" } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r510" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Preclinical and Clinical Research Expenses" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "Acquired in-process research and development" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research tax credit carryforward" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r131", "r771", "r798" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash", "totalLabel": "Restricted Cash, Total" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r8", "r20", "r131" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareOutstandingSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r41", "r427", "r506", "r714", "r800", "r827", "r832" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r150", "r151", "r152", "r156", "r164", "r166", "r283", "r503", "r504", "r505", "r550", "r551", "r638", "r823", "r825" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r219", "r220", "r233", "r239", "r240", "r246", "r247", "r249", "r444", "r445", "r752" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Revenues", "verboseLabel": "External revenues" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesScheduleOfRevenuesByCategoryDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureQuarterlyFinancialDataUnauditedScheduleOfQuarterlyFinancialDataDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfInformationByReportableSegmentsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r134", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r454" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r435" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "2020 Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r696", "r701" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "ROU assets obtained in exchange for new and amended operating lease liabilities", "verboseLabel": "Right-of-use assets obtained in exchange for new and amended operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSupplementalQuantitativeInformationRelatedToLeasesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Sale of stock proceeds, net" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity2019PublicOfferingOfCommonStockAndWarrantsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity2019RegisteredDirectOfferingAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockPurchaseAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityEquityDistributionAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsLicenseAgreementWithIcahnSchoolOfMedicineAtMountSinaiAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity2019PublicOfferingOfCommonStockAndWarrantsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity2019RegisteredDirectOfferingAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAspireTransactionAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockPurchaseAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithACEATherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithPersonalizedStemCellsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithTheTrusteesOfColumbiaUniversityInCityOfNewYorkAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityEquityDistributionAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Common stock sold in registered direct offering" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity2019RegisteredDirectOfferingAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAspireTransactionAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockPurchaseAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityEquityDistributionAgreementAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Stock price (USD per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity2019RegisteredDirectOfferingAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareOutstandingSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Components of Outstanding Securities" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Provision Expense (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r62", "r148", "r393", "r395", "r421", "r424", "r425", "r426", "r680", "r681", "r685", "r792" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-Term Debt and Unamortized Discount Balances" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Summary of Components of Net Deferred Tax Liabilities and Related Valuation Allowance" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Basic and Diluted Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Summary of Reconciliation Between Federal Income Tax and Company Provision for Income Taxes" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule Of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantstemAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r6", "r139", "r273", "r274", "r657" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule Of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantibodyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsNantstemAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r641", "r642" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r309", "r313", "r753" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfCompanySIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r309", "r313" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Summary of Company's Identifiable Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Loss Before Income Tax By Location" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Investments [Abstract]" } } }, "localname": "ScheduleOfInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Future Minimum Payments under Amended and Restated Loan and Security Agreement" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r50", "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of Quarterly Financial Data" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureQuarterlyFinancialDataUnauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r707", "r709" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r511", "r512" ], "lang": { "en-us": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAcquisitionOfAceaTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsAssetPurchaseAgreementWithAardvarkTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsLicenseAgreementWithIcahnSchoolOfMedicineAtMountSinaiAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSmartpharmTherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSofusaAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithACEATherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithNantcellAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithPersonalizedStemCellsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithTheTrusteesOfColumbiaUniversityInCityOfNewYorkAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsShortTermLoansAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "terseLabel": "Summary of Information by Reportable Segments" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r228", "r231", "r237", "r306" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfInformationByReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r472", "r497" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCommonStockReservedForFutureIssuanceAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansEmployeeStockPurchasePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansFairValueOfEmployeeAndDirectorStockOptionsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansScilexHoldingCompanyAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Unit (\"RSU\") Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r477", "r485", "r488" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Fair Value of Employee Stock Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r65", "r136", "r205", "r206", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r409", "r413", "r418", "r421", "r422", "r423", "r424", "r425", "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity2019PublicOfferingOfCommonStockAndWarrantsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAspireTransactionAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockPurchaseAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityEquityDistributionAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.", "label": "Schedule of Subsidiary or Equity Method Investee [Table]", "terseLabel": "Schedule Of Subsidiary Or Equity Method Investee [Table]" } } }, "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity2019RegisteredDirectOfferingAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r529", "r546" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Summary of Reconciliation of Unrecognized Tax Expense (Benefits)" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Estimated Future Amortization Expense Related to Intangible Assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r215", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r233", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r242", "r244", "r249", "r331", "r332", "r816" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfInformationByReportableSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r215", "r217", "r218", "r228", "r232", "r238", "r242", "r243", "r244", "r245", "r246", "r248", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfInformationByReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebtFutureMinimumPaymentsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service", "verboseLabel": "Service revenue" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesScheduleOfRevenuesByCategoryDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r122" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Outstanding options vesting anniversary period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights", "terseLabel": "Related party, option to purchase vesting rate description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of Shares, RSUs Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfRestrictedStockUnitRsuActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value Per Share, RSUs Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfRestrictedStockUnitRsuActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Unrestricted stock granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfRestrictedStockUnitRsuActivityDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value Per Share, RSUs Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfRestrictedStockUnitRsuActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Shares, Outstanding ending balance", "periodStartLabel": "Number of Shares, Outstanding beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfRestrictedStockUnitRsuActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value Per Share, Outstanding ending balance", "periodStartLabel": "Weighted-Average Grant Date Fair Value Per Share, Outstanding beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfRestrictedStockUnitRsuActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansFairValueOfEmployeeAndDirectorStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansFairValueOfEmployeeAndDirectorStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansFairValueOfEmployeeAndDirectorStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCommonStockReservedForFutureIssuanceAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansEmployeeStockPurchasePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansFairValueOfEmployeeAndDirectorStockOptionsDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansScilexHoldingCompanyAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Maximum percentage of their annual compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansEmployeeStockPurchasePlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r487" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options Canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansFairValueOfEmployeeAndDirectorStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r497" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r479", "r497" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options Outstanding ending balance (in shares)", "periodStartLabel": "Options Outstanding beginning balance (in shares)", "terseLabel": "Option outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansScilexHoldingCompanyAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in the weighted average exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price", "terseLabel": "Exercise price per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, ending balance (USD per share)", "periodStartLabel": "Weighted Average Exercise Price, beginning balance (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r470", "r475" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCommonStockReservedForFutureIssuanceAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansFairValueOfEmployeeAndDirectorStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options Exercised (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options Canceled (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options Granted (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r472", "r476" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Closing price of common stock" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Outstanding options exercisable period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans2019StockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r490", "r507" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of options (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansFairValueOfEmployeeAndDirectorStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Options Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Percentage of outstanding shares of common stock sold" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCEOPerformanceAwardAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansEmployeeStockPurchasePlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r432", "r509" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders' Equity and Share-based Payments [Text Block]", "terseLabel": "Stock Incentive and Employee Benefit Plans" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares (in shares)", "periodStartLabel": "Balance, shares (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r29", "r714", "r774", "r796" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Short-term borrowings", "totalLabel": "Short-term Debt, Total" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsShortTermLoansAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsShortTermLoansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r132", "r149" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Organization and Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r5", "r215", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r233", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r242", "r244", "r249", "r306", "r328", "r331", "r332", "r816" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfInformationByReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r36", "r37", "r38", "r136", "r139", "r171", "r174", "r186", "r190", "r193", "r205", "r206", "r207", "r274", "r349", "r353", "r354", "r355", "r358", "r359", "r404", "r405", "r409", "r413", "r420", "r657", "r855" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r69", "r93", "r94", "r95", "r150", "r151", "r152", "r156", "r164", "r166", "r204", "r283", "r420", "r427", "r503", "r504", "r505", "r550", "r551", "r638", "r672", "r673", "r674", "r675", "r676", "r677", "r823", "r824", "r825", "r868" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyAgreementsAndOtherAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCommonStockReservedForFutureIssuanceAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r150", "r151", "r152", "r204", "r752" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture", "terseLabel": "Stock-based compensation" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansEmployeeStockPurchasePlanAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r37", "r38", "r427" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance of common stock upon acquisition (in shares)", "verboseLabel": "Purchase of common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r68", "r380", "r420", "r421", "r427" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Issuance of common stock, conversion of notes payable (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r37", "r38", "r420", "r427" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r37", "r38", "r420", "r427", "r480" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Options Exercised (in shares)", "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansSummaryOfStockOptionActivityDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r69", "r420", "r427" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance of common stock upon acquisition", "verboseLabel": "Purchase of common stock, value" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r69", "r420", "r427" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of common stock, conversion of notes payable" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r37", "r38", "r420", "r427" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r69", "r420", "r427" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r38", "r43", "r44", "r139", "r255", "r274", "r657", "r714" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance", "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance", "totalLabel": "Total Sorrento Therapeutics, Inc. stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Sorrento Therapeutics, Inc. equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r94", "r139", "r150", "r151", "r152", "r156", "r164", "r274", "r283", "r427", "r503", "r504", "r505", "r550", "r551", "r596", "r597", "r612", "r638", "r657", "r672", "r673", "r677", "r824", "r825", "r868" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r137", "r405", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r419", "r427", "r432" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity1" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubordinatedDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents domestic or foreign subordinated debt. Subordinated debt has a lower priority of repayment in liquidation of the entity's assets.", "label": "Subordinated Debt [Member]", "terseLabel": "Subordinated Loan" } } }, "localname": "SubordinatedDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r678", "r716" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r678", "r716" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r678", "r716" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r678", "r716" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018PurchaseAgreementAndIndentureForScilexAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsAcquisitionOfSemnurPharmaceuticalsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r715", "r718" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEvents1" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureInvestmentsCelularityAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSignificantAgreementsAndContractsLicenseAgreementWithIcahnSchoolOfMedicineAtMountSinaiAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity2019PublicOfferingOfCommonStockAndWarrantsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity2019RegisteredDirectOfferingAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAspireTransactionAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityAtthemarketSalesAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquityCommonStockPurchaseAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureDebt2018SecuritiesPurchaseAgreementForPrivatePlacementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithACEATherapeuticsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithMayoFoundationAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithPersonalizedStemCellsIncAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureSignificantAgreementsAndContractsLicenseAgreementWithTheTrusteesOfColumbiaUniversityInCityOfNewYorkAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityEquityDistributionAgreementAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureStockholdersEquity2019RegisteredDirectOfferingAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "Liquidity and Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLiquidityAndGoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": { "auth_ref": [ "r513", "r514" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.", "label": "Tax Adjustments, Settlements, and Unusual Provisions", "terseLabel": "Changes in valuation allowance" } } }, "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r538" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Research and development credits" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r263", "r264", "r265", "r266", "r267", "r388", "r418", "r628", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r855", "r856", "r857", "r858", "r859", "r860", "r861" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r67", "r429" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r67", "r429" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "periodEndLabel": "Treasury Stock, Shares, Ending Balance", "periodStartLabel": "Treasury Stock, Shares, Beginning Balance", "terseLabel": "Treasury stock, shares (in shares)", "totalLabel": "Treasury Stock, Shares, Total" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r67", "r429", "r430" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, 7,568,182 shares at cost at December 31, 2021 and 2020", "periodEndLabel": "Treasury Stock, Value, Ending Balance", "periodStartLabel": "Treasury Stock, Value, Beginning Balance", "totalLabel": "Treasury Stock, Value, Total" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r155", "r156", "r157", "r158", "r168", "r259", "r260", "r280", "r281", "r282", "r283", "r285", "r286", "r348", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r548", "r549", "r550", "r551", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r658", "r659", "r661", "r662", "r663", "r664", "r665", "r666", "r702", "r754", "r755", "r756", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r864", "r865", "r866", "r867", "r868" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDiluted": { "auth_ref": [ "r188", "r191" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareReconciliationOfBasicAndDilutedEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings (loss), allocated to common stock, as if earnings and addition from assumption of issuance of common shares for dilutive potential common shares, had been distributed. Excludes distributed earnings.", "label": "Undistributed Earnings (Loss) Available to Common Shareholders, Diluted", "terseLabel": "Net loss attributable to Semnur holders of Scilex Holding", "totalLabel": "Undistributed Earnings (Loss) Available to Common Shareholders, Diluted, Total" } } }, "localname": "UndistributedEarningsLossAvailableToCommonShareholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareReconciliationOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r515", "r525" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxExpenseBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from acquisitions.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Acquisition", "terseLabel": "Increase related to acquisitions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxExpenseBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r526" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Decrease related to prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxExpenseBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r527" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increase related to current year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxExpenseBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r526" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Increase related to prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxExpenseBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r528" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Total unrecognized tax benefits, if recognized, would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r208", "r209", "r210", "r211", "r212", "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/DisclosureDebt2020RevolvingCreditFacilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareOutstandingSecuritiesDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockIncentiveAndEmployeeBenefitPlansCommonStockReservedForFutureIssuanceAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r170", "r193" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareReconciliationOfBasicAndDilutedEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted-average shares - diluted", "terseLabel": "Weighted-average shares outstanding during period - diluted shares attributable to Sorrento (in shares)", "totalLabel": "Denominator for loss earnings per share", "verboseLabel": "Weighted-average shares - diluted (shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareReconciliationOfBasicAndDilutedEarningsPerShareDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureQuarterlyFinancialDataUnauditedScheduleOfQuarterlyFinancialDataDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r169", "r193" ], "calculation": { "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareReconciliationOfBasicAndDilutedEarningsPerShareDetails": { "order": 0.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted-average shares - basic", "terseLabel": "Weighted-average shares outstanding during period - basic shares attributable to Sorrento (in shares)", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "verboseLabel": "Denominator for basic loss per share" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureLossPerShareReconciliationOfBasicAndDilutedEarningsPerShareDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_DisclosureQuarterlyFinancialDataUnauditedScheduleOfQuarterlyFinancialDataDetails", "http://sorrentotherapeutics.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7,9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1828-109256" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2062-109256" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "48", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2538-109256" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "48", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2538-109256" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2574-109256" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2597-109256" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2600-109256" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "54", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2603-109256" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "66", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2814-109256" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=d3e1280-108306" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL124452896-108306" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=124268079&loc=d3e32787-111569" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r275": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r299": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r329": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r335": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123389529&loc=d3e10037-110241" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123408193&loc=d3e12803-110250" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r399": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r432": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r454": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r509": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28511-109314" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28446-109314" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e34017-109320" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r563": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e845-128460" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e848-128460" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90198-114008" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r7": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r711": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r718": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(d)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column E)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column F)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=123877278&loc=SL120174030-210619" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r847": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r848": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r849": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r850": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r851": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r852": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r853": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r854": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r855": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r856": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r857": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r858": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r859": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r860": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r861": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r862": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r863": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" } }, "version": "2.1" }